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ABSTRACT 
Cardiovascular diseases are the major cause of death worldwide. It is a group of diseases, which 
affect the heart, the vasculature and the brain. Lifestyle and metabolic risk factors are major 
contributors to cardiovascular ill-health. In addition to these risk factors, a growing number of 
scientific studies show that some environmental pollutants, e.g. lead and mercury, can adversely 
affect cardiovascular health. Despite the increasing amount of knowledge from human and animal 
studies, cardiovascular effects of lead, mercury species or their mixtures are not well understood. It 
is also unknown if safe exposure thresholds for these metals exist or the underlying mechanisms of 
action for the elicitation of cardiovascular toxicity.   
 
The first set of studies had the objectives to elucidate the range of effects of single exposure to lead, 
inorganic mercury or methylmercury on the cardiovascular system. Therefore, male Wistar rats were 
exposed to a broad range of doses of lead, inorganic mercury or methylmercury for four weeks 
through the drinking water. Cardiovascular health of the rats was assessed by measuring the blood 
pressure and the cardiac electrical activity after four weeks of exposure, while the heart function and 
blood flow in the carotid artery was measured at baseline and at the end of the exposure duration. 
The study showed that all three metals differ in their effects on the cardiovascular system. Lead 
showed bi-phasic dose-response curves for several cardiovascular end-points. No cardiovascular 
effects were observed for inorganic mercury, while methylmercury showed linear dose-response 
curves. Based on these results, safe levels of exposure for lead and methylmercury were derived.    
 
The second study applied the same experimental design as the previous study in order to 
investigate the cardiovascular effects of combined exposures to lead, inorganic mercury and 
methylmercury. The mixture ratios were based on reference and exposure values published in the 
scientific literature. The adverse cardiovascular effects, which were observed for single exposures 
were reversed for the mixtures indicating antagonism. In contrast to single exposures, mixtures 
negatively affected the electrical activity of the heart (synergism), which could lead to arrhythmias 
and heart failure.  
 
The third set of studies focused on the exploration of oxidative stress, kidney function and damage, 
and global DNA methylation as potential mechanisms of action for the development of elevated 
blood pressure. Results for lead showed an increase in oxidative stress but not mercury. While only 
lead was associated with kidney damage, only inorganic mercury was related to altered global DNA 
methylation. Methylmercury appears to elevate blood pressure through a not investigated 
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mechanism. Therefore, oxidative stress and kidney damage seem to be associated with elevated 
blood pressure but not global DNA methylation.   
 
Overall, the research presented in this thesis shows that lead, inorganic mercury and methylmercury 
and their mixtures have the ability to adversely affect the cardiovascular system. However, each 
metal affected the cardiovascular system differently and surprisingly, mixtures showed antagonism 
or synergism depending on the examined end-point, which was reflected in the results of the 
mechanistic study. As health problems of the cardiovascular system, e.g. hypertension, occur mainly 
in the adult population and in particular the elderly, cardiovascular effects should be considered as 
an important end-point for this age group in addition to neurodevelopmental effects in children.   
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1 GENERAL INTRODUCTION 
1.1 Introduction 
Non-communicable diseases, such as cardiovascular diseases (CVDs) or cancer, have exceeded 
the number of deaths from communicable diseases (Laslett et al., 2012). Presently, CVDs are 
responsible for more than 17 million per year, which renders this disease group the major cause of 
death worldwide. Taking into account that the number of deaths is expected to pass 23 million by 
2030, heart attacks and stroke, as the most important representatives for CVDs pose an important 
public health problem (WHO, 2014). Cardiovascular diseases are chronic and characterized by long 
disease duration, slow progression and their potential prevention through a reduction of risk factors 
(WHO, 2013). 
During previous decades, more and more risk factors were discovered and were categorized as 
behavioral, physiological/metabolic and socio-economic risk factors. Unhealthy behaviors include 
cigarette smoking, lack of exercise, high salt diets or excess consumption of alcohol (Mendis et al., 
2011). These risk factors can lead to metabolic disturbances (Danaei et al., 2009) by increasing 
blood pressure (hypertension), blood sugar (diabetes), blood lipids (hyperlipidemia) or body weight 
(overweight/obesity) (Laslett et al., 2012), which constitute risk factors of their own. In contrast to the 
behavioral risk factors, CVDs can also be the result of the patient’s genetic make-up, gender or age. 
Finally, the socio-economic environment, e.g. low income and education status, and psychological 
factors contribute to the development of atherosclerosis, which is a risk factor of its own for CVDs 
(Mendis et al., 2011). Atherosclerosis is characterized by a complex pathological process, which 
leads to the narrowing of blood vessels. The risk for a heart attack or stroke increases with the 
number of existing risk factors (The Conference Board of Canada, 2010). 
While the prevalence of some risk factors, such as tobacco use, declined in many parts of the world, 
obesity and hypertension increased (Laslett et al., 2012). Since 1980, the number of obese men and 
women doubled worldwide, reaching 10% for men and 14% for women (Malik et al., 2013). 
However, obesity rates passed 30% in North America, in parts of Latin America, North Africa and the 
Middle East (Malik et al., 2013). A similar trend can be observed with blood pressure. While in 1980 
about 600 million adults over the age of 25 years were diagnosed with hypertension, in 2008, this 
number had risen to almost one billion corresponding to about 40% (Mendis et al., 2011). 
Over the next 15 years, it is expected that the costs associated with CVDs will rise from US$863 
billion to US$20 trillion (Mensah et al., 2014). These costs can be allocated to direct health costs, 
such as hospitalization, medication and physician care, and indirect costs, which result in economic 
 2 
losses (Tarride et al., 2009). The impaired health of patients suffering from CVDs leads to a reduced 
quality of life through disabilities and premature death (Tarride et al., 2009). 
1.1.1 Rationale 
There is increasing evidence that exposure to lead or mercury species is a risk factor for the 
development of cardiovascular diseases. In particular, the association between lead exposure and 
hypertension is considered to be causal (Nawrot et al., 2002; Navas-Acien et al., 2007; Scinicariello 
et al., 2011). Although the picture for mercury species is less clear, studies exist which indicate an 
association between mercury exposure and cardiovascular effects (Vupputuri et al., 2005; Bautista 
et al., 2009; Lim et al., 2010; Roman et al., 2011). As CVDs can be prevented by a reduction of risk 
factors, it is worth investigating the cardiovascular effects of exposures to lead and mercury species 
in more detail. 
The overall purpose of this research was to elucidate the cardiovascular effects of exposure to lead 
or mercury species alone or their mixtures and to investigate underlying mechanisms of action for 
cardiovascular toxicity. Due to the limited availability of studies on a broad variety of cardiovascular 
end-points and often inconclusive results, the first step was to investigate the effects of single metal 
exposure on the cardiovascular system. In a second step, effects of combined exposures, which 
better reflect the real-life situation of humans, on the cardiovascular system were assessed. The last 
step was to explore different mechanisms of actions on how single and combined metal exposures 
induce cardiovascular toxicity.  
1.1.2 Hypotheses 
As part of this research project the following hypotheses were examined: 
1. Exposure to lead (Pb(II)), inorganic mercury (Hg(II)) or methylmercury (MeHg(I)) will 
adversely affect blood pressure, heart function, blood flow and electrical activity of the heart 
in rats.  
2. Concomitant exposure to Pb(II), Hg(II) and MeHg(I) will aggravate the cardiovascular effects 
of single metal exposures.  
3. The three metals Pb(II), Hg(II) and MeHg(I) will induce cardiovascular toxicity through the 
same mechanism of action.  
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1.1.3 Objectives 
The objectives of this research project were investigated by the following three experiments: 
Experiment 1: Which are the effects on the cardiovascular system due to single exposure to 
Pb(II), Hg(II) or MeHg(I) in adult male rats? 
1. To investigate cardiovascular health, blood pressure, heart function, blood flow and cardiac 
electrical conductivity were measured in adult male rats.  
2. To derive safe exposure levels for Pb(II), Hg(II) and MeHg(I), which are protective against 
hypertension, from the animal studies for the human adult population.  
Experiment 2: What are the effects on the cardiovascular system due to combined exposure 
to Pb(II), Hg(II) and MeHg(I) in adult male rats?  
1. To determine mixture effects, such as synergism or antagonism, from mixtures containing 
Pb(II), Hg(II) and MeHg(I). 
2. To investigate the influence of the ratio between Pb(II), Hg(II) and MeHg(I) on the 
cardiovascular end-point.  
3. To evaluate if mixture effects of Pb(II), Hg(II) and MeHg(I) on the cardiovascular system can 
correctly be predicted from single metal exposures. 
Experiment 3: Through which mechanism(s) of action do Pb(II), Hg(II) and MeHg(I) and their 
mixtures elicit cardiovascular toxicity? 
1. To investigate oxidative stress levels, kidney function and global DNA methylation status as 
potential mechanisms of action.  
2. To identify differences between single metal exposure and combined exposure on 
cardiovascular end-points.  
1.2 Organization of the dissertation 
The research in this dissertation is presented in manuscript format following the style requirements 
of peer-reviewed journals. The introduction in Chapter 1 and the literature review in Chapter 2 
provide an overview of the overall research topic. Each manuscript-based chapter (Chapters 3 – 5) 
starts with a preface, which links the specific content of the manuscript to the thesis as a whole. The 
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remainder of the chapters follows the structure of a scientific article: abstract, introduction, materials 
and methods, results, discussion and conclusions. 
The three manuscript-based research chapters address the following objectives: 
Chapter 3: Investigate the range of adverse cardiovascular effects resulting from single exposure to 
Pb(II), Hg(II) or MeHg(I) in rats to broaden the understanding of relevant cardiovascular end-points, 
Chapter 4: Explore the cardiovascular effects of combined exposures to Pb(II), Hg(II) and MeHg(I) 
and evaluate the usefulness of single metal exposure effects for predicting mixture effects, 
Chapter 5: Analyze effects of single and combined exposures of Pb(II), Hg(II) and MeHg(I) on 
reactive oxygen species/antioxidant balance, kidney function and global DNA methylation status to 
understand how these mechanisms of action interact in the development of cardiovascular toxicity.  
The final chapter (Chapter 6) interprets the major research results as a whole and provides 
recommendations based on open questions for future research. This chapter is followed by a 
reference section (Chapter 7). Chapter 8 contains appendices A-C. Appendix A includes 
supplementary data to Chapter 3. Appendix B presents results on cardiovascular effects from single 
and combined exposures to Pb(II), Hg(II) and MeHg(I), which were not published in the scientific 
literature. Appendix C includes permissions for the use of accepted manuscripts in the thesis.   
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2 LITERATURE REVIEW 
2.1 Introduction 
Cardiovascular diseases are a group of diseases, which affect the brain, heart and blood vessels 
(Mendis et al., 2011). With growing age and depending on the number of existing risk factors, the 
risk of CVDs increases. Therefore, adults and in particular elderly are the main population group 
affected by this group of diseases. 
 
2.2 Parameters of cardiovascular health 
2.2.1 Blood and pulse pressure 
Blood pressure is the pressure of the blood on the arterial walls. The systolic blood pressure value 
(higher value) represents the pressure at the time when the blood is ejected from the heart and the 
diastolic blood pressure (lower value) when the ventricles are filling with blood (Levy and Pappano, 
2007a).  
A standard method to assess cardiovascular health is the measurement of the blood pressure 
because it can be measured fast and non-invasively in humans. The two organs, which are 
responsible for blood pressure regulation, are the brain and the kidneys (Osborn, 2005; Herrera and 
Coffman, 2012). However, the detailed mechanism is not entirely known. The blood pressure can be 
regulated through the heart rate, stroke volume and the total peripheral resistance (Raven and 
Chapleau, 2014). The brain has the ability to influence the heart, kidneys, blood vessels and adrenal 
medulla through the autonomic nervous system, consisting of the sympathetic and parasympathetic 
arm (Osborn, 2005). Through the release of chemicals and hormones into the blood, the heart 
contractility can be altered and thus, changing the cardiac output, which is the product of the heart 
rate and stroke volume. Furthermore, the brain can adjust the blood volume through the kidneys and 
alter the resistance and capacitance of the blood vessels. The kidneys have the ability to control 
long-term blood pressure regulation through sodium excretion (Herrera and Coffman, 2012). 
Although blood pressure varies throughout the day to adapt to changing environmental conditions, a 
constantly increased blood pressure is considered to be an important risk factor for the development 
of CVDs. A formalized classification scheme for blood pressure allows the identification and 
categorization of humans as normotensive or hypertensive (Table 2.1). 
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Table 2.1. Blood pressure classification (WHO/ISH, 2003) 
 
Category Systolic (mmHg) Diastolic (mmHg) 
Optimal < 120 < 80 
Normal < 130 < 85 
High-normal 130-139 85-89 
Grade 1 hypertension (mild) 140-159 90-99 
Grade 2 hypertension (moderate) 160-179 100-109 
Grade 3 hypertension (severe) ≥ 180 ≥ 110 
 
With regard to the development of CVDs, it is also important to identify additional risk factors in the 
patients, because of their accumulative nature (Table 2.2). 
Table 2.2: Risk stratification table (WHO/ISH, 2003) 
 Blood pressure (mmHg) 
Other risk factors and disease history Grade 1 Grade 2 Grade 3 
No other risk factors Low risk Medium risk High risk 
1-2 risk factors Medium risk Medium risk High risk 
3 or more risk factors, target-organ damage, 
associated clinical conditions 
High risk High risk High risk 
 
Probability of developing a major cardiovascular event within the next 10 years: Low risk: < 15%; medium risk: 15-
20%; high risk: > 20% 
Although the prevalence of hypertension in the adult population is high, in the majority of patients the 
cause remains often unknown (essential hypertension) and only symptoms are treated (Chen, 
2012). In half of the cases, the reason for the presence of increased blood pressure can be related 
to genetics. However, most of the time more than one gene is involved. The other half can be 
attributed to epigenetic mechanisms, i.e. interaction between genes and the environment. 
Environmental factors or risk factors, e.g. smoking, stress, overweight, can positively contribute to 
the development of hypertension. Secondary hypertension exists if an underlying disease, e.g. 
diabetes mellitus or chronic renal disease, is the cause (Bateman et al., 2012).  
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Based on the blood pressure measurements, the pulse pressure can be calculated by subtracting 
the diastolic blood pressure value from the systolic value. Changes in pulse pressure can indicate 
arterial stiffness and an increased risk for atherosclerosis.  
2.2.2 Heart function 
The heart consists of four chambers, two atria and two ventricles. The blood coming from the 
systemic cycle enters the heart through the right atrium. From here the blood flows to the right 
ventricle and enters the pulmonary cycle. The blood re-enters the heart through the left atrium and 
flows then to the left ventricle (Levy and Pappano, 2007b). With every beat of the heart, blood is 
ejected from the left ventricle into the aortic arc. The heart function can be assessed by determining 
the end-systolic and end-diastolic volumes, whose difference provides the stroke volume. Another 
parameter for heart function is the cardiac output, which is the product of the heart rate and the 
stroke volume.  
2.2.3 Blood vessels and blood flow 
The structure of blood vessels depends on their main function. Big arteries, e.g. the aorta, consist of 
a high amount of elastic tissue allowing the change from pulsatile to laminar flow (Pappano, 2008). 
The small capillaries, which facilitate the exchange of nutrients and oxygen, basically consist of only 
the endothelium. Measuring the wall thickness or diameter of major arteries, such as the carotid, or 
different blood flow parameters, it is possible to evaluate the health of the artery.  
2.2.4 Cardiac electrical activity 
The heart is innervated by the autonomic nervous system. However, the different chambers of the 
heart are not all depolarized or repolarized at the same time but in a specific order. The electrical 
activity of the heart can be recorded with an electrocardiograph and made visible on an 
electrocardiogram (ECG) (Pappano, 2008). The first peak in an ECG (P wave) corresponds to the 
activation of the atria. While the atria relax, the ventricles are activated resulting in a second wave 
(QRS complex). The following T wave reflects the repolarization of the ventricles. Based on the 
ECG, it is possible to identify irregularities in the heart beat, activation and relaxation of the 
chambers (arrhythmia), which can indicate disturbances in the electrical activity of the heart.  
2.3 Lead 
2.3.1 Occurrence and exposure 
The Earth’s crust naturally contains ores including lead, mainly as galena (PbS), anglesite (PbSO4) 
or cerussite (PbCO3). About 30% of the worldwide lead reserves are located in North America 
(ATSDR, 2007) with Canada being among the top 10 producers and suppliers of refined lead 
(Panagapko, 2009). Lead is mainly used in the production of lead-acid storage batteries. These 
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types of batteries play an important role in the car and communications industries. Due to its 
resistance to corrosion, it is used in paints for iron and steel and in roofs. It is also used in a variety 
of screens because of its ability to prevent the release of potentially damaging radiation. Additional 
uses are in plastic piping and decorative glass (Panagapko, 2009). Overall, lead possesses many 
useful properties, which makes it a desirable substance in various industries. Workers employed in 
these industries can be exposed to lead fumes and dust at their work place. Therefore, regulations 
are in place to restrict the amount and exposure duration in occupational settings. Additionally, the 
implementation of safety measures, e.g. lead-free areas, allows to minimizing exposure to lead. In 
the case of an accident, high exposures for a short term can occur.  
Because of the extensive use of lead in manufacturing, processing and production facilities, it is 
released into the environment, where it is ubiquitously present. Through the deposition of lead from 
the air on agricultural soils or water surfaces, it will reach the food chain rendering food and water 
the main exposure sources for the general population. Tobacco plants have the ability to accumulate 
lead from the soil, which renders cigarettes and cigarette smoke another potential source for lead. In 
older homes, lead-containing paint might constitute an additional exposure source (ATSDR, 2007).  
To protect the general population from ill-health due to lead exposure, governmental agencies, e.g. 
Health Canada, have established an intervention level for lead of 10 µg/dL blood for adults and 5 
µg/dL blood for children based on neurological effects. At this level, it is recommended to take action 
to reduce exposure. Generally, the blood lead levels (BLL) in the Canadian population are below 2 
µg/dL blood (Statistics Canada, 2008). However, as adverse effects were observed at blood levels < 
5 µg/dL, no reference values are defined. 
2.3.2 Toxicokinetics 
The main route of exposure for lead is by ingesting food and water. Once the lead particles have 
reached the gastro-intestinal tract, they can be absorbed into the blood circulation. The absorption 
rate depends on a number of different factors, such as nutritional status, age, meal status (ATSDR, 
2007). In the blood, lead is mainly found in the erythrocytes with a half-life of about 30 days 
(Rabinowitz et al., 1976). With the blood, lead is distributed in the whole organism but will eventually 
be deposited in bones where it can remain for decades. Excretion occurs through urine and feces. 
2.3.3 Toxic effects  
2.3.3.1 Neurotoxicity 
Traditionally, lead is considered to act as a neurotoxicant with neurodevelopmental toxicity as the 
most sensitive end-point. Hence, the majority of studies investigate the neurobehavioral effects of 
lead exposure on children as the most vulnerable population group. Children show decreased 
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cognitive and academic skills at a BLL ≤ 5 µg/dL (Lanphear et al., 2000). In an adult population 
recruited from the third National Health and Nutrition Examination Survey (NHANES III) a BLL of 
≤ 25 µg/dL did not result in any adverse neurobehavioral effects (Krieg et al., 2005). Due to life-long 
accumulation of lead in the bones, the elderly might be another vulnerable population group. 
Although the association between bone lead and cognitive tests is weak (Weisskopf et al., 2007), the 
coordination between vision and motor skills might be adversely affected.  
2.3.3.2 Cardiovascular toxicity 
The scientific literature provides sufficient evidence to consider the relation between lead exposure 
and the development of hypertension as causal (Nawrot et al., 2002; Navas-Acien et al., 2007; Hara 
et al., 2014). As the prevalence of hypertension increases with age, adults and elderly might be the 
most vulnerable population group for impaired cardiovascular health due to lead exposure. Few 
studies explored other cardiovascular end-points than blood pressure. Peripheral arterial disease 
(PAD) is a disease affecting the blood vessels, whose blood flow is limited due to the presence of 
atherosclerosis. Navas-Acien et al (2004) found a positive association between mean BLLs of 2 
µg/dL and PAD. This association could not be confirmed for urinary lead (Navas-Acien et al., 2005). 
Similar BLLs also showed an increased risk of mortality from heart attacks and strokes (Menke et al., 
2006; Schober et al., 2006). A study by Cheng et al (1998) showed a relation between a BLL of 5.8 
µg/dL and disturbances of the cardiac electrical conductivity. The lengths of the QT and QRS 
intervals increased with higher lead body burden.  
2.3.3.3 Nephrotoxicity 
Lead has also the ability to impair kidney function resulting in secondary hypertension. Data from 
large human studies, such as NHANES and the Normative Aging Study, indicate a direct relation 
between lead body burden and chronic kidney disease and hypertension (Muntner et al., 2003; 
Tsaih et al., 2004). Similarly, BLLs ≤10 µg/dL were associated with a reduced glomerular filtration 
rate (Kim and Lee, 2012) or kidney damage (Sommar et al., 2013).  
2.4 Mercury 
2.4.1 Occurrence and exposure 
Similar to lead, mercury is naturally occurring in the Earth’s crust. Mercury vapor can be released 
into the environment naturally through volcanic eruptions or from natural sinks like the ocean but 
also through human activities, such as burning of coal or waste (Clarkson, 2002). This process 
indicates the start of global mercury cycling. Once the mercury vapor has reached the atmosphere, it 
can be oxidized and deposited to the ground by rainfall. The Hg(II) is biomethylated to MeHg(I) 
followed by accumulation in predatory fish and seafood, which constitutes one of the major exposure 
sources for humans. Dental amalgam, which contains 50% mercury, provides a second source for 
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human exposure (Bellinger et al., 2006). In an occupational setting, dentist and other dental staff 
might be at risk during the preparation and placing of amalgam fillings (Richardson, 2003), unless 
suitable protection is applied (Goodrich et al., 2013b). The general population will be exposed to 
mercury vapor starting with the dental treatment. As the amalgam fillings will continue to release 
mercury vapor, the low level exposure becomes long-term (Mutter, 2011; Richardson et al., 2011).  
 
2.4.2 Toxicokinetics 
MeHg(I) and mercury vapor are both easily absorbed. The lipophilicity of MeHg(I) facilitates the 
absorption from the gastro-intestinal tract into the blood (Clarkson et al., 2007). This chemical 
property also allows MeHg(I) to cross membranes, such as the blood-brain or blood-placenta 
barriers (Ballatori, 2002). It also has a high affinity to thiol-groups and can easily bind to 
biomolecules, e.g. glutathione or cysteine (Bridges and Zalups, 2005). If MeHg(I) binds to cysteine, 
the resulting molecule resembles the amino acid methionine. By mimicking this neutral amino acid, 
MeHg(I) can use transporters to cross membranes and to cause toxic effects (Bridges and Zalups, 
2005). Instead of normal amino acids, the MeHg(I)-cysteine compound is incorporated into hair, 
which makes it a good biomarker for MeHg(I) exposure. Finally, MeHg(I) is mainly excreted through 
the feces. 
As a gas, mercury vapor has the ability to diffuse through membranes and thus cross the blood-brain 
and blood-placenta barriers leading to a high absorption rate (Clarkson et al., 2007). Once it has 
reached the blood, it is quickly oxidized to Hg(II), which is assumed to be the toxic form (Clarkson et 
al., 2007). With the blood, the Hg(II) will be transported to other organs, e.g. spleen, liver or kidneys, 
where it might accumulate. Although a small amount of the mercury vapor is exhaled, most of it will 
be excreted as Hg(II) through the urine and feces (Clarkson et al., 2007).  
2.4.3 Toxic effects  
2.4.3.1 Neurotoxicity 
As Pb(II), mercury is classically considered to be a neurotoxicant with the developing brain as the 
main target organ. Due to two major accidents poisoning people in Japan and Iraq, the neurotoxic 
effects of MeHg(I) are well known.  
From 1950 to 1970, a factory released MeHg(I) into the Minamata River, Japan, which accumulated 
in fish in this area. Because of the consumption of this contaminated fish, people living around 
Minamata Bay were chronically exposed to MeHg(I) (Minamata disease) (Ekino et al., 2007). 
Although children are more sensitive to neurotoxicity because of their still developing brains, the 
exposure was high enough to also cause neurotoxicity in the adult population. In the early 1970s, 
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another MeHg(I) poisoning occurred in Iraq because of contaminated seed grain (Bakir et al., 1980). 
As the exposure was sufficiently high, children as well as adults were affected.   
To study neurodevelopmental effects from MeHg(I) contained in the diet, two large cohort studies 
were started in the 1980s. One study location is the Faroe Islands between Iceland and the United 
Kingdom. The other study was carried out in the Seychelles, which are east of the African coast and 
north of Madagascar. Due to their different locations and climates, the diets differed substantially. In 
the Faroe Islands the main exposure source for MeHg(I) is whale meat, while in the Seychelles, it is 
ocean fish and seafood. Both studies focused on neurobehavioral end-points in children to assess 
developmental neurotoxicity. In the Faroe Islands, cognitive deficits, e.g. in language skills, were 
found. However, the overall picture is not entirely clear (Grandjean et al., 2012). Analyzing the 
potential contribution of polychlorinated biphenyls to the neurobehavioral deficits, it was concluded 
that their effect was minor in comparison to MeHg(I) (Grandjean et al., 2012). In the Seychelles, no 
association between prenatal exposure to methylmercury and neurophysiological skills were 
observed (Davidson et al., 2011). The researchers could also not find an association between 
prenatal exposure to mercury vapor through amalgam fillings of the mother and neurodevelopmental 
effects in the children (Watson et al., 2011). Although MeHg(I) causes neurotoxic effects at higher 
doses as observed in Japan and Iraq, the neurodevelopmental effects of prenatal MeHg(I) exposure 
in children are less clear.  
Dentists and dental staff are occupationally exposed to mercury vapor when handling amalgam 
fillings. Several research groups have studied the relation between occupational exposure to 
mercury vapor in dentists and dental staff and neurobehavioral effects. Although behavioral changes 
were only subtle, Echeverria et al (1995) could show a positive relation in dentists between urine 
mercury as a biomarker for elemental mercury exposure and reduced mental concentration, 
emotional lability and mood scores. Similarly, dental assistants (Moen et al., 2008; Hilt et al., 2009) 
experienced more often psychosomatic symptoms, memory and concentration problems, and 
fatigue. 
2.4.3.2 Cardiovascular toxicity 
Although no causative relation as with Pb(II) and hypertension exists, there is growing scientific 
evidence for an association between mercury exposure and adverse effects on the cardiovascular 
system (Roman et al., 2011; Houston, 2014). The general population is mainly exposed to MeHg(I) 
through the consumption of fish and seafood. At the same time, fish also contains heart-protective 
compounds, such as long-chain n-3 fatty acids. Therefore, study results might differ for fish and non-
fish eaters. Fillion et al (2006) studied a fish-eating Amazonian population in Brazil. Hair mercury 
was positively associated with blood pressure, although overall blood pressure was rather low. 
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Vupputuri (2005) could not show an overall relation between mercury exposure and blood pressure. 
However for non-fish eating women aged from 16-49 years an increase in systolic blood pressure 
was observed. Bautista et al (2009) found a positive association between blood and hair mercury 
and increased blood pressure. Valera et al studied the relation between environmental mercury 
exposure and cardiovascular end-points in a number of different populations and countries. Inuit 
adults from Nunavik, Canada, are exposed to MeHg(I) through the consumption of marine mammals 
and predatory fish as part of their traditional diet (Valera et al., 2008). Valera et al (2008; 2009) 
found that blood mercury was positively associated with systolic blood pressure and pulse pressure. 
Dietary mercury exposure reduces heart rate variability (Lim et al., 2010; Valera et al., 2008), which 
is a sign for impaired cardiac autonomic activity through parasympathetic dysfunction. Mercury level 
was associated with increased risk for heart attacks (Guallar et al., 2002). Goodrich et al (2013b) 
investigated the relation between MeHg(I) exposure (hair as biomarker) and mercury vapor 
(biomarker urine) and blood pressure. Hair mercury was positively associated with blood pressure, 
while urine mercury was negatively associated with blood pressure.  
The association between MeHg(I) exposure and the development of hypertension is corroborated by 
animal studies by Grotto et al. Wistar rats received MeHg(I)-chloride for the duration of 100 days at a 
dose of 100 µg/kg-bw/d by gavage (Grotto et al., 2009). After only four weeks of exposure, the 
systolic blood pressure (30 mmHg) was increased in exposed rats compared to the control group. In 
a follow-up study, rats were exposed to MeHg(I) simulating the diet of an Amazon riverside 
population (Grotto et al., 2011) by adding fish from a contaminated area in Northern Brazil and 
uncontaminated fish from an area in Southern Brazil. The final rat diet contained 20% fish and 80% 
normal rat food, which corresponds to the contribution of fish to the overall food consumption in the 
Amazonian population. After 11 weeks of exposure, the rats exposed to the contaminated fish 
showed an increase in systolic blood pressure (20 mmHg). 
The second source for mercury exposure is dental amalgam fillings with dental staff and people with 
dental amalgam fillings as the target groups. Siblerud (1990) observed a positive association 
between people with amalgam fillings and increased blood pressure and decreased heart rate. After 
the removal of the amalgam fillings, the people reported an improvement of cardiovascular health 
and overall better well-being. As dental staff is exposed to mercury vapor by preparing and handling 
amalgam fillings, this professional group is of particular interest. The health status of dentists was 
evaluated by analyzing pharmacy utilization data (Duplinsky and Cicchetti, 2012). The overall 
conclusion of this study was that the dentists had more health problems than the control group due 
to a higher consumption of e.g. cardiovascular medications (Duplinsky and Cicchetti, 2012). 
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2.4.3.3 Nephrotoxicity 
Mercury vapor is quickly oxidized to Hg(II), which accumulates in the kidneys. Therefore, mercury in 
urine provides a good biomarker for exposure to elemental mercury (Clarkson et al., 2007). While 
high exposure to Hg(II) can cause renal failure, low-level exposures have only subtle effects on 
biomarkers for kidney function (Li et al., 2012). Glutathione-S-transferases, which indicate damage 
of the proximal tubules, were elevated in children bearing dental amalgam (Geier et al., 2014). 
People living close to a mercury mine in China (Li et al., 2012) showed increased values for serum 
creatinine and serum urea nitrogen, which are signs for impaired kidney function, for increasing 
blood mercury levels.  
 
2.5 Mechanisms of action 
Lead and mercury are systemic toxicants and can elicit toxicity through a number of different 
mechanisms of actions (MOAs), which can occur in parallel or interact with each other. The best-
known MOA for metals is the production of oxidative stress by impairing the balance between 
reactive oxygen species (ROS) and antioxidants. These ROS can disturb biochemical pathways, 
damage cells or react with other biomolecules. If this happens in the kidneys, they might not be able 
anymore to carry out their control function to regulate the blood pressure. Epigenetic mechanisms 
are gaining more and more importance in the development of non-communicable diseases, e.g. 
CVDs. As metals have the potential to affect gene expression, a consequence could be the 
impairment of cardiovascular health. 
2.5.1 Oxidative stress 
Oxidative stress occurs when the balance between reactive oxygen species, e.g. superoxide, 
hydrogen peroxide, or nitrogen species (RNS) and antioxidants is disturbed. Both parts of this 
system play important roles in the regulation of physiological functions. Nitric oxide (NO) as a 
representative of an RNS acts as a vasodilator and hence, is an important for the blood pressure 
regulation. However, if due to an imbalance the amount of ROS increases, then these molecules can 
harm DNA or biomolecules in general (Valko et al., 2007).  
Metals are well known to have the ability to increase the production of ROS through Fenton-like 
reactions:  
M
(n)
 + O2
-∙→ M(n-1) + O2 
M
(n-1)
 + H2O2 → M
(n)
 + HO∙ + OH- 
Fig. 2.1. Fenton-like reactions (Ercal et al., 2001) 
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In case of an imbalance of the ROS/antioxidant system, various defense mechanisms are employed 
(Valko et al., 2007): 1) preventative mechanisms, 2) repair mechanisms, 3) physical defenses and 4) 
antioxidant defenses. Glutathione (GSH) is an important antioxidant in the prevention of oxidative 
damage. However, both lead and mercury have a high affinity for thiol-groups and by binding to 
these groups of glutathione result in glutathione inactivation (Bridges and Zalups, 2005).   
Studies have shown that Hg(II) causes an imbalance between ROS and antioxidants in several 
ways. It was shown that Hg(II) increases the production of O2
-
 in the vasculature (Wiggers et al., 
2008) and thus oxidative stress. The radical O2
-
 can then damage the endothelium, which is an 
important producer of the vasodilator NO. As a consequence, the bioavailability of NO is reduced 
(Wiggers et al., 2008). Hg(II) also contributes to oxidative stress by oxidizing GSH and has the ability 
to cause cell damage (Wolf and Baynes, 2007). MeHg(I) is also cytotoxic and increases oxidative 
stress but through raised NO levels (Huang et al., 2008). Due to its high affinity to thiol-groups, 
MeHg(I) also reacts with GSH resulting in its depletion (Hagele et al., 2007). Mercury vapor does not 
seem to increase oxidative stress (Goering et al., 2002). In biological systems, Pb(II) induces 
oxidative stress by reducing NO availability (Gonick et al., 1997) and the depletion of GSH (Vaziri et 
al., 2000). Instead of measuring the amount of molecules, increased enzyme activities of e.g. 
superoxide dismutase, catalase or glutathione peroxidase are also an indicator of oxidative stress 
(Farmand et al., 2005). In summary, Pb(II) and Hg species have the ability to reduce the availability 
of the vasodilator NO by e.g. cytotoxicity, and to increase the number of ROS. At the same time, the 
antioxidant GSH is inactivated, which aggravates the effect of oxidative stress on the organism. 
Finally, by disturbing the balance between ROS and antioxidants, Pb(II) and Hg species will increase 
the blood pressure and the risk for CVDs (Vaziri, 2008; Houston, 2014). 
To evaluate the amount of oxidative stress caused by the exposure to Pb(II) or Hg species and their 
mixtures, the 3-nitrotyrosine levels in blood were measured. Under normal circumstances, 3-
nitrotyrosine is very low. In the case of increased oxidative stress production, NO is decreased, while 
O2
-
 is increased. Both molecules react with each other and from peroxynitrite, which then reacts with 
tyrosine residues in proteins.  
NO + O2
-
 → ONOO- + tyrosine → 3-nitrotyrosine 
Therefore, an increase of 3-nitrotyrosine is a sign of increased oxidative stress.  
In addition to assess oxidative stress, glutathione levels were measured as a representative of an 
antioxidant. In the event of oxidative stress, the reduced form of glutathione (GSH) is oxidized to 
glutathione disulfide (GSSG) (Wolf and Baynes, 2007). The ratio of GSSG to GSH is generally small 
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because a healthy cell contains more GSH than GSSG. Hence, an increased ratio is deemed to be a 
sign for oxidative stress. 
2.5.2 Kidney damage 
Lead and Hg species are known nephrotoxicants, which will impair kidney function with increasing 
body burden. As the kidneys play an important role in the regulation of blood pressure due to their 
ability to regulate sodium excretion, kidney damage can be considered as a metabolic risk factor for 
CVDs. Therefore, kidney function was assessed as a MOA for lead and Hg species toxicity for 
cardiovascular health.   
Creatinine originates from muscle metabolism and as muscle mass is quite stable on a day-to-day 
basis, creatinine is as well. Furthermore, it is freely filtrated by the nephrons in the kidney and can be 
used as a marker for overall kidney function. Creatinine clearance is a clinical standard for assessing 
kidney function by providing an estimate of the glomerular filtration rate, which equals the volume of 
blood being cleared of creatinine through urine excretion per minute. It is defined as the product of 
the creatinine concentration in urine and urine flow divided by the creatinine concentration in plasma. 
However, creatinine clearance is not a very sensitive marker (Vlasakova et al., 2014) because 
healthy nephrons have the ability to compensate for damaged ones. Therefore, a decrease in 
creatinine clearance is a sign for substantial nephron damage (Schnellmann, 2008). Despite this 
weakness, blood and urine creatinine concentrations were measured, urine flow obtained from the 
literature and the creatinine clearance was calculated, which is regularly obtained in patients.  
To complement the creatinine clearance test with a more sensitive marker, levels of the kidney injury 
molecule 1 (KIM-1) levels in urine were measured. KIM-1 is a protein, which is expressed by the 
tubular epithelial cells in the kidney due to injury. In comparison to other markers for kidney function 
(Vlasakova et al., 2014), it is a sensitive marker for evaluating damage of the kidney tubules.  
2.5.3 Epigenetic mechanism 
Epigenetics describes the interactions between genes and the environment. In contrast to mutations 
in genetics, epigenetic effects do not alter the DNA sequence. Three epigenetic mechanisms 
regulate the expression of proteins by switching genes on and off. The best studied mechanism is 
DNA methylation. DNA methyltransferases (DNMTs) transfer methyl-groups from S-
adenosylmethionine (SAM) to cytosine-guanine (CpG) dinucleotides at the carbon-5 position in 
cytosine. The second mechanism is the modification of histones, which organize DNA into 
nucleosomes. Modification, e.g. deacetylation or methylations, takes place at the N-terminal tails 
resulting in a silencing of the gene (Fuks, 2005). Furthermore, histone modifications can interact with 
DNA methylation in order to regulate gene expression (Hashimoto et al., 2010). The last mechanism 
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refers to the non-coding RNA (ncRNA), which consist of long and small ncRNA (Cheng et al., 2012). 
While small ncRNA participate in the regulation of gene expression through the silencing of genes, 
long ncRNA play a role in genomic imprinting (Choudhuri, 2011).  
An increasing body of studies indicates the involvement of epigenetic mechanisms in a broad variety 
of diseases. Therefore, it is likely that these mechanisms are a potential mode of action for the 
development of cardiovascular diseases because of exposure to lead or mercury species. It can be 
assumed that these metals either affect directly or indirectly genes, which are involved in the 
maintenance of cardiovascular health. However, little scientific evidence exists to substantiate this 
relation.  
For recent exposure, blood lead levels are the preferred biomarker, while bone lead is an indicator 
for long-term exposure. Wright et al (2010) found a positive association between bone lead and DNA 
methylation but not with blood lead levels. This might indicate that the total body burden due to 
chronic lead exposure is necessary for changes in DNA methylation. As cardiovascular diseases are 
more pronounced after a certain age, this might support the link between lead bone levels and the 
development of CVDs. In a study by Kovatsi et al (2010), blood lead was related to altered 
methylation of the p16 promoter gene, which is involved in the death of neurons. Although this rather 
indicates a mechanism for neurotoxicity, cardiovascular health could indirectly be impaired through 
disturbances in the autonomic nervous system. Histone modifications are not attributed to lead 
exposure (Fragou et al., 2011).  
As MeHg(I) is considered to be very toxic to the developing fetus, a couple of studies exist, which 
investigated prenatal exposure to methylmercury. Pregnant rats were exposed to high doses of 
methylmercury (Desaulniers et al., 2009). The off-spring had decreased mRNA levels for DNMT and 
DNA methylation in the liver. In a study by Onishchenko (2008) prenatal exposure to MeHg(I) lead to 
signs of depression in the off-spring through hypomethylation of the brain-derived neurotrophic 
factor. Mercury decreased the methylation of growth factors required for normal neurodevelopment 
(Waly et al., 2004). It was also observed that mercury blood levels are directly associated with 
increased methylation of the glutathione-S-transferase M1 gene, indicating a risk for oxidative stress 
(Hanna et al., 2012). In contrast, an indirect relation exists between DNA methylation and brain 
mercury levels (Pilsner et al., 2010). Overall, no study was identified, which investigated the effect of 
lead and/or mercury exposure on genes relevant for cardiovascular health.  
A small number of studies investigated the effect of altered DNA methylation of enzymes relevant for 
cardiovascular homeostasis exploring critical steps in DNA methylation as a potential mechanism of 
action. Hypomethylation of the enzyme 11 beta-hydroxysteroid dehydrogenase type 2 (11beta-
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HSD2) reduces its activity. At the same time, mineralocorticoid receptors are activated, which result 
in increased sodium retention in the kidneys and as a consequence in an increase in blood pressure 
(Fragou et al., 2011; Friso et al., 2008). Another epigenetic mechanism of action for the development 
of hypertension could be the DNA methylation of the ace-1 genes as shown by Riviere (2011). 
These genes code for the angiotensin-converting enzyme (ACE), which plays an important role in 
blood pressure regulation. The enzyme ACE facilitates the conversion of angiotensin I to angiotensin 
II, a vasopressor, and deactivates the vasodilator bradykinin. Another important vasodilator NO 
could be affected in a similar way. Chan et al (2004) observed in a number of different cell types that 
hypomethylation of the gene for the endothelial NO synthase (eNOS) decreases the expression of 
the eNOS mRNA leading to a reduced availability of NO. While these molecular studies provide 
information on the mechanism of action, studies analyzing the global DNA methylation status are 
able to link an epigenetic mechanism to a physiological outcome and thus, complement the picture. 
Smolarek et al (2010) analyzed the global DNA methylation status in the blood of patients with 
essential hypertension. Hypomethylation was associated with severity of hypertension. Similarly, in a 
study by Baccarelli et al (2010) hypomethylation of blood LINE-1 was associated with increased 
risks for ischemic heart disease, stroke and total mortality. In the Chinese population in Singapore, 
Kim et al (2010) explored if DNA methylation could be used as a biomarker for cardiovascular 
diseases, such as heart attacks or strokes, or metabolic risk factors, e.g. hypertension, diabetes. 
Although the study indicates an association between DNA methylation and increased blood pressure 
or cardiovascular diseases, this can only be considered as a very first step towards the development 
of an epigenetic biomarker for cardiovascular diseases.  
Based on the scientific literature, it seems very likely that DNA methylation constitutes a potential 
mechanism of action for the development of CVDs, including CVDs due to exposure to lead or 
mercury exposure. The actual mechanism of action will have a high grade of complexity because of 
the high number of genes involved in the maintenance of cardiovascular health. As the amount of 
studies investigating this topic is very limited, it is not possible to conclusively say there is a role for 
DNA methylation in the development of CVDs.  
As part of this research, the amount of 5-methyl-2’deoxycytidine in urine was analyzed as a marker 
for global DNA methylation. The purpose was to explore the effect of single and combined 
exposures to lead and mercury species on the overall DNA methylation status and to potentially link 
this epigenetic mechanism to cardiovascular effects.  
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2.6 Human health risk assessment 
Risk assessments estimate the potential risk on human health by taking into account the toxicity of 
the substance and exposure. Depending on the amount of available data, this process can be time-
consuming and challenging.  
 
2.6.1 Risk assessment of single metal exposure 
A risk assessment is a defined process, which consists of four steps. The first step is the hazard 
identification, which evaluates inherent properties of the substance, which might cause adverse 
effects. The dose-response assessment (step 2) and the exposure assessment (step 3) can be 
carried out in parallel and complement each other providing the necessary information for the risk 
characterization (step 4). While step 2, investigates potential health problems at defined exposures, 
step 3 explores exposures in the population group in question. Findings from these steps are 
required to finalize the risk assessment (U.S. EPA, 2012). Conclusions based on the outcome of a 
risk assessment will identify the type and size of a potential risk in the general population as well as 
vulnerable groups, e.g. children.   
In case of a sufficient database for the substance and the most sensitive end-points, governmental 
agencies establish a safe dose of exposure. The U.S. EPA calls this dose reference dose (RfD) and 
defines it as “an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral 
exposure to the human population (including sensitive subgroups) that is likely to be without an 
appreciable risk of deleterious effects during a lifetime. No-observed-adverse-effect level (NOAEL) 
and lowest-observed-adverse-effect level (LOAEL) can be derived from the dose-response curves 
(U.S. EPA, 2014b). The RfD can be derived from a NOAEL, LOAEL, or benchmark dose, with 
uncertainty factors generally applied to reflect limitations of the data used” (U.S. EPA, 2014c). If the 
NOAEL or LOAEL were derived from animal data, uncertainty factors for inter- and intra- species 
variability can be applied to determine safe exposure levels for the protection of human health. 
Additional uncertainty factors can be applied to protect vulnerable groups, such as children, elderly, 
immunocompromised people. The U.S. EPA (2014b) defines a BMD as “a dose that produces a 
predetermined change in response rate of an adverse effect (called the benchmark response or 
BMR) compared to background”. Depending on the agency and country, these safe doses are called 
RfD by U.S. EPA or provisional tolerable daily intake (pTDI) by Health Canada and in Europe. 
No RfD or pTDI exist for lead exposure and developmental neurotoxicity or adult nephrotoxicity 
because the available database indicates that even low exposures have an adverse effect so that no 
safe dose exists. Using the BMD approach, EFSA (2012b) has derived BMDLs01 identifying a 95
th
 
percentile lower confidence limit of the benchmark dose of 1% extra risk for developmental 
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neurotoxicity in children, cardiovascular toxicity and nephrotoxicity in adults with 0.5, 1.5 and 0.63 
µg/kg-bw/d, respectively. 
Mercury toxicity depends on its chemical form. Hence, safe exposure levels are established for 
organic mercury, namely MeHg(I), and Hg(II). Based on the U.S. EPA Integrated Risk Information 
System (IRIS) (U.S. EPA, 2014d) the RfD for MeHg(I) is 0.1 µg/kg-bw/d for neurodevelopmental 
effects, while the RfD for Hg(II) is 0.3 µg/kg-bw/d with autoimmune effects as end-point. In contrast, 
to a daily exposure dose, EFSA (2012a) established tolerable weekly intakes (TWI). The TWI of 
Hg(II) was determined as 4 µg/kg-bw for nephrotoxicity, which corresponds to a daily tolerable intake 
of 0.6 µg/kg-bw/d. MeHg(I) has a TWI of 1.3 µg/kg-bw for neurodevelopmental effects, which equals 
a daily tolerable intake of 0.2 µg/kg-bw/d. Discrepancies in the doses considered as safe can be 
explained with the use of different datasets and end-points. However, it can be assumed that the 
human population is protected by these values due to the application of uncertainty factors in their 
calculations.  
2.6.2 Risk assessment of metal mixture exposure 
The human population is generally exposed to a mixture of substances because of the ubiquitous 
presence of chemicals in the environment. However, experiments in animals or cells often use only 
one substance to evaluate its toxicity. Although studies in humans would allow studying mixture 
effects, e.g. by measuring total mercury and BLLs, it is rarely done. Hence, risk assessments of 
mixtures often present a big challenge because of the lack of suitable and sufficient data.  
The US EPA guidelines for the health risk assessment of chemical mixtures (U.S. EPA, 1986) 
provide guiding principles on how to assess the risk of chemical mixtures. A critical step in the risk 
assessment is to obtain sufficient data on exposure and toxicity of the mixture of concern. In case, 
this is not possible, it is suggested to consider data on similar mixtures, e.g. same components but 
different concentrations, or on single components of the mixture. Depending on the quality and 
quantity of the available data, the conclusions of the risk assessment will contain varying degrees of 
uncertainty.  
Government agencies have established safe levels of exposure for many chemicals, e.g. Pb and Hg, 
which allows the risk assessor to estimate the risk of a mixture for human health by calculating the 
hazard index (HI) (U.S. EPA, 1986). In the case of HI, the safe level of exposure is called acceptable 
level (AL). As with full risk assessments, the HI assumes additivity of substances and is defined as  
HI = E1/AL1 + E2/AL2 + … + Ei/Ali 
with Ei = exposure level to the i
th
 toxicant and ALi = maximum acceptable level for the i
th
 toxicant. 
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The assumption of additivity of mixture components indicates that the single mixture components do 
not interact with each other. This may lead to an under- or overestimation of risk due to synergistic 
or antagonistic effects. As interaction data are often missing, further uncertainty is introduced.  
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3 CARDIOVASCULAR RESPONSES TO LEAD ARE BIPHASIC, WHILE 
METHYLMERCURY, BUT NOT INORGANIC MERCURY, 
MONOTONICALLY INCREASES BLOOD PRESSURE IN RATS 
 
3.1 Author contributions 
Tanja M. Wildemann carried out the animal experiment, including the daily care of the animals, 
measurements of the cardiovascular effects, termination and tissue collection and processing. 
Furthermore, she conducted the statistical analysis and prepared the manuscript.  
Naghmeh Mirhosseini assisted in the termination of the animals, sample collection and processing 
and provided comments on the manuscript.  
Steven D. Siciliano provided scientific input, provided comments on the manuscript and supported 
the research financially through his research grant. 
Lynn P. Weber provided scientific input and guidance, edited the manuscript and supported the 
research financially through her research grant.  
3.2 Preface 
Most studies on cardiovascular effects of Pb(II) and mercury species originate from epidemiological 
studies, which have the inherent disadvantage of limited control over confounding factors, such as 
smoking or comorbidities. For ethical reasons, it is also not possible to carry out invasive 
interventions. To be able to investigate the association between Pb(II), Hg(II) and MeHg(I) exposure 
and a broad range of cardiovascular effects, we opted for an animal model. Using rats as our model, 
we were able to explore cardiovascular effects, such as blood pressure, heart function, blood flow 
and electrical activity of the heart, at different doses of these three metals in a controlled 
environment. This allowed us to derive dose-response curves for each metal and the selected 
cardiovascular end-points and to determine safe thresholds of exposure.  
Published as Wildemann, T.; Mirhosseini, N.; Siciliano, S.D., Weber, L.P. (2015) Cardiovascular 
responses to lead are biphasic, while methylmercury, but not inorganic mercury, monotonically 
increases blood pressure in rats, Toxicology 328, 1-11 doi 10.1016/j.tox.2014.11.009 
3.3 Abstract  
Cardiovascular diseases, such as heart attack and stroke, are the major cause of death worldwide. It 
is well known that a high number of environmental and physiological risk factors contribute to the 
development of cardiovascular diseases. Although risk factors are additive, increased blood 
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pressure (hypertension) is the greatest risk factor. Over the last two decades, a growing number of 
epidemiological studies associate environmental exposure to lead or mercury species with 
hypertension. However, cardiovascular effects beyond blood pressure are rarely studied and 
thresholds for effect are not yet clear. To explore effects of lead or mercury species on the 
cardiovascular system, normal male Wistar rats were exposed to a range of doses of lead, inorganic 
mercury or methylmercury through the drinking water for four weeks. High-resolution ultrasound was 
used to measure heart and vascular function (carotid artery blood flow) at baseline and at the end of 
the exposure, while blood pressure was measured directly in the femoral artery at the end of the 4-
week exposure. After 4 weeks, blood pressure responses to lead were biphasic. Low lead levels 
decreased blood pressure, dilated the carotid artery and increased cardiac output. At higher lead 
doses, rats had increased blood pressure. In contrast, methylmercury-exposed rats had increased 
blood pressure at all doses despite dilated carotid arteries. Inorganic mercury did not show any 
significant cardiovascular effects. Based on the current study, the benchmark dose level 10% 
(BMDL10s) for systolic blood pressure for lead, inorganic mercury (based on systemic toxicity) and 
methylmercury are 1.1, 1.3 and 1.0 µg/kg-bw/d, respectively. However, similar total mercury blood 
levels attributed to inorganic mercury or methylmercury produced strikingly different results with 
inorganic mercury having no observable effect on the cardiovascular system but methylmercury 
increasing systolic and pulse pressures. Therefore, adverse cardiovascular effects cannot be 
predicted by total blood mercury level alone and the mercury species of exposure must be taken into 
account.   
 
3.4 Introduction 
Heavy metals, such as lead (Pb) and mercury (Hg), are mobilized in the environment mainly through 
anthropogenic sources, such as mining and industrial activities, rendering them ubiquitously present 
in the environment (ATSDR, 2007; Health Canada, 2013; EFSA, 2012a). The principal exposure 
route for lead is oral through food and drinking water (Health Canada, 2013; ATSDR, 1999; EFSA, 
2012a). The absorption of lead depends on a variety of factors, such as age or the nutritional status 
of the person. In the body, lead is bound to the erythrocytes and more than 90% of the total body 
burden in adults can be found in the bones (ATSDR, 2007). Two mercury species are relevant for 
human exposure, namely elemental mercury (Hg
0
) and methylmercury (MeHg). While exposure to 
elemental mercury primarily arises through inhalation from dental amalgam fillings (Richardson, 
2014), methylmercury accumulates in predatory fish and seafood, which leads to dietary exposure in 
humans (Clarkson, 2002). Elemental mercury is vaporous and hence very mobile. It can easily cross 
the blood brain barrier, but is also quickly oxidized to inorganic mercury in the blood and other 
tissues (Clarkson et al., 2007), leading to deposition of inorganic mercury in target organs such as 
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liver or kidneys. Methylmercury is readily absorbed in the gut and distributes in all tissues, including 
the brain. It can be converted in the body to inorganic mercury or methylmercury-cysteine which can 
mimic the amino acid methionine (Clarkson et al., 2007; Ballatori, 2002). Thus, human 
environmental mercury exposure can be modeled with inorganic mercury and methylmercury.  
Although both lead and mercury are considered to have neurological effects as their primary toxicity, 
a growing body of epidemiological research associates lead exposure (mostly blood lead levels) with 
adverse cardiovascular health. Data from population-based studies, including the National Health 
and Nutrition Examination Survey (NHANES) or the Normative Aging Study, show clear associations 
between low blood lead levels (≤ 10 µg/dl) and hypertension (Scinicariello et al., 2011; Cheng et al., 
2001; Glenn et al., 2003; Nash et al., 2003). Only a few studies using the NHANES database 
examined additional cardiovascular end-points beyond hypertension. Specifically, positive 
associations were shown between blood lead levels (≥ 2 µg/dL) and increased mortality due to 
myocardial infarction and stroke (Menke et al., 2006; Schober et al., 2006), increased risk of 
peripheral arterial disease (Navas-Acien et al., 2004) or abnormalities in electrocardiogram (ECG) 
data consistent with left ventricular hypertrophy (Schwartz, 1991). A few rat studies support a cause-
effect relationship between chronic lead exposure and hypertension (Nowack et al., 1993; Ding et 
al., 1998; Fiorim et al., 2011). Furthermore, Skoczynska et al (2014) exposed rats to lead through 
the drinking water and then measured heart function with cardiac magnetic resonance imaging 
(MRI). This study showed that the cardiac ejection fraction and fractional area change in the lead-
exposed rats were significantly reduced in comparison to the control rats indicating impaired cardiac 
function. There is evidence for a causal relationship between blood lead levels and hypertension as 
well as additional cardiac effects but thresholds for adverse effects remain unclear.  
The connection between mercury exposure and cardiovascular health is much less clear. In human 
studies, the most common biomarker of exposure is total mercury levels in blood which is generally 
thought to indicate recent exposure to inorganic and organic mercury (Health Canada, 2010). 
Another biomarker of exposure is mercury levels in hair samples which are generally thought to 
relate to methylmercury exposure (Li et al., 2008). Some epidemiological studies (Bautista et al., 
2009; Valera et al., 2009; Pedersen et al., 2005) found a positive association between blood or hair 
mercury levels and an increased risk for hypertension and pulse pressure. However, other studies in 
humans (Vupputuri et al., 2005; Johansson et al., 2002; Mozaffarian et al., 2011; 2012; Valera et al., 
2011a; Park et al., 2013) did not find a link between blood mercury levels and blood pressure or 
cardiovascular diseases (Mozaffarian et al., 2011). Higher mercury levels in hair or blood samples 
were associated with reduced heart rate variability (a known risk factor for cardiovascular death) in 
Koreans (Lim et al., 2010), Nunavik Inuits (Valera et al., 2008) and Canadian Cree adults (Valera et 
al., 2011a). Furthermore, Salonen et al (2000) found a positive association between hair mercury 
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levels and carotid atherosclerosis in a Finnish cohort study. Finally, dentists and dental staff are 
occupationally exposed to mercury vapor, which is quickly metabolized to inorganic mercury, 
through the handling of dental amalgam. Using pharmacy utilization data, Duplinsky and Cicchetti 
(2012) showed that dental professionals at the age of 45 and above have a higher prescription rate 
for cardiovascular medication than the general population, further supporting the link between higher 
mercury exposure and increased risk for cardiovascular disease. In summary, while human studies 
show an association between mercury exposure and cardiovascular health, the specific mercury 
species responsible and the thresholds for cardiovascular effect remain unclear. 
Animal studies have also suggested a link between mercury and adverse cardiovascular effects. In 
rat studies, although inorganic mercury (50 µg HgCl2/ml in the drinking water for 320 days or 4.6 
µg/kg injected loading dose plus daily 0.07 µg/kg/day i.m.) failed to significantly affect blood pressure 
(Carmignani et al., 1983; Blanco-Rivero et al., 2011; Furieri et al., 2011a) other studies using the 
same doses have reported increased vasoconstriction in isolated arteries (Blanco-Rivero et al., 
2011; Golpon et al., 2003; Furieri et al., 2011b) or reduced cardiac contractility in isolated rat hearts 
(Furieri et al., 2011a; Souza de Assis et al., 2003). In contrast, methylmercury exposure in rats (0.5 
mg MeHg/kg-bw oral gavage for 23 – 28 days or a 10-fold higher dose) led to latent increases in 
systolic blood pressure either at 42 days or immediately after exposure, respectively (Wakita, 1987) . 
In another study, rats gavaged with 100 µg/kg-bw/d methylmercury for 100 days also had 
significantly increased systolic blood pressure after four weeks (Grotto et al., 2009). Therefore, 
animal studies are highly suggestive of a causative association between methylmercury exposure 
and adverse cardiovascular effects, while the relationship between inorganic mercury and 
cardiovascular effects are unclear. However, thresholds for adverse cardiovascular effects for both 
mercury species require clarification.  
We hypothesized that exposures to lead, inorganic mercury or methylmercury will adversely affect 
cardiovascular function in rats. In order to investigate adverse effects of lead versus differing 
mercury species on the cardiovascular system, as well as the thresholds for these effects, we 
examined effects of a broad range of metal doses in normal male Wistar rats. In order to generate 
data that could be used to assess risk to humans through oral exposure, rats were exposed to lead 
acetate, mercury chloride or mono-methylmercury chloride for 28 days via the drinking water. 
Cardiovascular end-points evaluated included cardiac and vascular function, assessed by high-
resolution ultrasound in B-mode and power Doppler mode, respectively; direct (intravascular) blood 
pressure was measured in the femoral artery, and cardiac electrical activity through 
electrocardiography (ECG) analyses at the end of the 4-week exposure.  
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3.5 Materials and methods  
3.5.1 Animals 
Male Wistar rats (250 – 300 g) were purchased from Charles River Laboratories, Canada and 
acclimatized for one week before the start of the experiment. The animals were housed singly at the 
Western College of Veterinary Medicine at the University of Saskatchewan (Saskatoon, SK, 
Canada). They were housed at 22°C under a 12:12h-light dark cycle with free access to standard rat 
chow. All experiments were approved by the University of Saskatchewan’s Animal Research Ethics 
Board and carried out according to the guidelines of the Canadian Council on Animal Care (CCAC). 
For the duration of four weeks, rats were exposed (n = 5-6) to either lead acetate (Pb(II)), mercury 
chloride (Hg(II)) or mono-methylmercury chloride (MeHg(I)) through ad libitum drinking water (tap 
water with 0.2% nitric acid). Rats were exposed to broad ranges of lead acetate (4, 7, 14, 29, 57, 
357, 1607, 45000 µg/kg-bw/d) or mercury chloride (7, 14, 29, 57, 357, 2000, 4000, 8000 µg/kg-bw/d) 
or mono-methylmercury chloride (4, 7, 14, 29, 57, 357, 1607 µg/kg-bw/d) based on published studies 
and LD50 (Grotto et al., 2009; Carmignani et al., 1983; 1992; Malvezzi et al., 2001; Jin et al., 2012). 
Average water consumption was assumed to be 10-12 ml/kg-bw/d, which would result in an 
expected water consumption of 40-50 ml per day and rat in this study. Based on these values for 
water consumption, the metal concentrations in the drinking water were calculated to achieve the 
above mentioned dose ranges. Control rats (n = 9) received tap water with 0.2% nitric acid. All 
chemicals were obtained from Sigma-Aldrich (Oakville, ON, Canada).  
3.5.2 High-resolution cardiovascular ultrasound, arterial blood pressure and 
electrocardiography 
At baseline and after four weeks of exposure, heart function and blood flow in the carotid artery of 
the anesthetized rats (isoflurane 5% and oxygen 1mL/min to induce, isoflurane 1-3% and oxygen 
0.5mL/min for maintenance) were examined using a high-resolution B-mode and power Doppler 
ultrasound, respectively (Visualsonics Vevo 770, Toronto, ON, Canada). Prior to anesthesia, rats 
were injected with 3 ml saline (s.c.) and placed on a heated platform controlled by a rectal 
thermometer to maintain body temperature at 37°C. All measurements were carried out as described 
and performed previously in our laboratory (Boon, 2011; Jadhav et al., 2013). Briefly, for cardiac 
function the length of the left ventricle in systole and diastole were each measured in triplicate views 
of the parasternal long axis in B-mode followed by three cross-sectional areas (A1, A2, A3) taken at 
the parasternal short axis using Visualsonics software or exporting TIFF images for off-line analysis 
of left ventricular free wall thickness (Image-Pro Express 6.0, MediaCybernetics Inc, USA, 2006). 
Ventricular length and cross-sectional area values were used in Simpson’s rule (Boon, 2011) to 
calculate left ventricular volumes at end-systole (ESV) and end-diastole (EDV). An image of the 
carotid artery just prior to the bifurcation was taken first in B-mode to determine arterial luminal 
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diameter and arterial wall thickness, followed by power Doppler to measure pulse-wave velocity. 
Stroke volume (SV) was calculated as the difference between EDV and ESV, while cardiac output 
was calculated as the product of heart rate (HR) and SV, which are presented after 4 weeks of 
exposure. Due to large inter-individual variation evident at baseline (see Supplemental Table S8.1 
for baseline data), results for free wall thickness of the heart (Figure 3.3), carotid diameter and free 
wall thickness as well as peak velocity (Figure 3.4) are presented as the difference between week 4 
exposure and baseline values for each individual rat.  
After the final ultrasound examination, rats were allowed to recover for 24 h before measurement of 
blood pressure, heart rate and electrical activity of the heart using Lead II on a Powerlab system and 
analysed using LabChart 7.0 (software (ADInstruments, Colorado Springs, CO, USA), followed 
immediately by euthanasia and tissue collection. Prior to blood pressure and ECG measurements, 
rats were injected with 3 ml saline (s.c.) and placed on a 37°C heating blanket to maintain body 
temperature. A saline-filled pressure catheter connected to a PowerLab was inserted into the 
femoral artery for intravascular blood pressure measurement after calibration with a mercury column 
(ADInstruments, Colorado Springs, CO, USA). Averaged values from blood pressure, heart rate and 
ECG (PR, QRS and QT intervals) over 10 minutes were used in statistics. Blood and pulse pressure 
as well as heart rate are presented after 4 weeks of exposure.  
3.5.3 Blood analysis 
Lead and mercury levels in whole blood samples were analyzed by the Prairie Diagnostic Services 
Inc. located at the Western College of Veterinary Medicine at the University of Saskatchewan 
(Saskatoon, SK, Canada). The blood samples were digested with concentrated nitric acid (70%) in a 
Mars Microwave Accelerated Reaction System (CEM, Matthews, NC, USA) and digested samples 
analyzed with Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) (Thermo Scientific X Series 
2, Waltham, MA, USA) against standard reference materials.  
3.5.4 Statistical analysis 
All results expressed as mean ± standard deviation (SD). Data were tested for normality and 
homogeneity of variance using Kolmogorov-Smirnov and Bartlett’s tests. All data satisfied these 
requirements for parametric statistics after outliers were removed. Differences among groups were 
detected by one-way Analysis of Variance (ANOVA) followed by Fisher’s Least Significant Difference 
(LSD) post-hoc test (GraphPadPrism, GraphPad Software, Inc, San Diego, CA, USA). A p < 0.05 
was considered significant. NOAELs (no observed adverse effects level) and LOAELs (lowest 
observed adverse effects level) were directly derived from the study results based on increases in 
systolic blood pressure since this is the endpoint with the clearest link to increased cardiovascular 
risk. The highest dose of a given metal producing no statistically significant increase in pressure was 
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determined to be the NOAEL, while the lowest dose producing a significant increase in pressure was 
considered the LOAEL. An alternative to the NOAEL-LOAEL approach is the benchmark dose 
(BMD) lower-limit approach using a 10% confidence (BMDL10). We used US EPA BMD software 2.5 
(U.S. EPA, 2014a) to calculate BMDL10s for systolic blood pressure for the three metals. For lead, 
we did not include doses which produced a decrease in blood pressure since this effect is not clearly 
associating with adverse cardiovascular risk. Instead we used an exponential model and doses of 29 
µg/kg-bw/d and higher, which showed either no effect or an increase on blood pressure. For both Hg 
species a polynomial model fit and the full dose range was used. 
3.6 Results 
3.6.1 Growth performance and blood metal analysis 
All doses of lead were sub-lethal since no mortalities were observed over the 4-week period of 
exposure. Lead-exposed rats showed a significantly greater weight gain at low to moderate doses 
(ranging from 4 – 57 µg/kg-bw/d) compared to rats from the control group (Table 3.1). In contrast, 
rats from the three highest lead dose groups gained a similar amount of weight as control rats (Table 
3.1). No significant differences among lead-exposed rats compared to control rats were observed in 
the relative weights of brain, heart, kidney and liver (expressed as percent body weight; Table 3.1). 
However, spleen weight tended to be higher in all lead-exposed groups compared to control, 
achieving significance in 7, 29, 357 and 45,000 µg/kg-bw/d lead groups (Table 3.1). In contrast to 
lead, inorganic mercury exposure at the highest dose of 8000 µg/kg-bw/d showed severe signs of 
toxicity (significant weight loss, reduced food and water intake, reduced grooming; Table 3.1). This 
toxicity was evident within a week and was severe enough that all rats of this treatment group had to 
be terminated after only two of the four-week exposure (values for rats after 2-weeks exposure 
shown in Table 3.1). The rats from this highest dose group would have likely died before the end of 
the 4-week exposure and thus this highest dose was considered a 100% lethal dose. All rats from 
lower inorganic mercury doses examined in this study did not exhibit obvious toxicity and thus were 
considered sub-lethal. After 2-weeks exposure to the highest inorganic mercury, relative brain and 
heart weight were significantly higher in this 8000 µg/kg-bw/d group compared to control. In addition, 
inorganic mercury exposure for 4 weeks at the next two highest doses plus the highest dose after 2-
weeks exposure led to higher kidney weights compared to control (i.e. kidney weight increased for 
Hg(II) ≥ 357 µg/kg-bw/d; Table 3.1). No mortalities were observed due to methylmercury exposure at 
any of the doses examined in the current study. In contrast to inorganic mercury, methylmercury-
exposed rats showed only mild signs of toxicity (reductions in grooming, food intake and weight gain) 
and only at the highest dose of 1607 µg/kg-bw/d (Table 3.1). Furthermore, this highest 
methylmercury group showed increased brain, increased kidney and decreased liver weights 
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compared to control rats (Table 3.1). Therefore, all methylmercury doses in this study could be 
considered sub-lethal.  
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Table 3.1. Morpholometric values and mortality of rats exposed to lead acetate, mercury chloride or monomethyl-mercury chloride versus 
control (0.9% nitric acid) in the drinking water for four weeks. 
Experimental 
dose  
(µg/kg-bw/d) 
Change in 
bodyweight 
(g) 
Brain/body 
weight (%) 
Heart/body 
weight (%) 
Kidneys/body 
weight (%) 
Liver/body 
weight (%) 
Spleen/body 
weight (%) 
Mortality (%) 
Control 
0 113 ± 19 0.38 ± 0.05 0.26 ± 0.02 0.66 ± 0.05 3.58 ± 0.36 0.20 ± 0.02 0 
Pb(II) 
4 188 ± 23**** 0.41 ± 0.04 0.26 ± 0.04 0.70 ± 0.03 3.86 ± 0.37 0.21 ± 0.04 0 
7 224 ± 27**** 0.39 ± 0.03 0.26 ± 0.03 0.75 ± 0.03 4.03 ± 0.33 0.25 ± 0.02** 0 
14 165 ± 17** 0.42 ± 0.05 0.29 ± 0.01 0.77 ± 0.07 4.33 ± 0.32 0.25 ± 0.02 0 
29 209 ± 34**** 0.41 ± 0.06 0.25 ± 0.01 0.71 ± 0.08 3.54 ± 0.31 0.24 ± 0.04* 0 
57 217 ± 32**** 0.41 ± 0.04 0.26 ± 0.02 0.70 ± 0.06 3.85 ± 0.30 0.22 ± 0.03 0 
357 106 ± 22 0.40 ± 0.03 0.26 ± 0.02 0.70 ± 0.04 3.71 ± 0.31 0.24 ± 0.04* 0 
1607 121 ± 29 0.39 ± 0.03 0.24 ± 0.01 0.70 ± 0.08 3.78 ± 0.34 0.21 ± 0.02 0 
45000 113 ± 33 0.38 ± 0.03 0.24 ± 0.01 0.70 ± 0.04 3.81 ± 0.37 0.26 ± 0.03*** 0 
Hg(II) 
7 133 ± 14 0.41 ± 0.03 0.25 ± 0.02 0.71 ± 0.08 3.59 ± 0.30 0.22 ± 0.01 0 
14 97 ± 19 0.40 ± 0.03 0.26 ± 0.02 0.67 ± 0.06 3.50 ± 0.22 0.20 ± 0.01 0 
29 130 ± 31 0.41 ± 0.01 0.25 ± 0.03 0.68 ± 0.07 3.55 ± 0.31 0.19 ± 0.04 0 
57 112 ± 10 0.40 ± 0.02 0.26 ± 0.02 0.70 ± 0.04 3.28 ± 0.36 0.20 ± 0.02 0 
357 137 ± 18 0.41 ± 0.02 0.25 ± 0.02 0.76 ± 0.05* 3.42 ± 0.45 0.22 ± 0.02 0 
2000 88 ± 26 0.37 ± 0.07 0.25 ± 0.02 0.83 ± 0.10*** 3.41 ± 0.29 0.24 ± 0.03 0 
4000 90 ± 24 0.40 ± 0.02 0.26 ± 0.02 0.87 ± 0.07**** 3.58 ± 0.40 0.21 ± 0.03 0 
8000 -72 ± 92**** 0.59 ± 0.11**** 0.30 ± 0.03** 1.17 ± 0.16**** 3.70 ± 0.46 0.21 ± 0.09 100 
Values shown are mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 in Fisher’s LSD after 1-way ANOVA. n=5-6 rats/group 
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Table 3.1. Morpholometric values and mortality of rats exposed to lead acetate, mercury chloride or monomethyl-mercury chloride versus 
control (0.9% nitric acid) in the drinking water for four weeks (continued). 
Experimental 
dose (µg/kg-
bw/d) 
Change in 
body weight 
(g) 
Brain/body 
weight (%) 
Heart/body 
weight (%) 
Kidneys/body 
weight (%) 
Liver/body 
weight (%) 
Spleen/body 
weight (%) 
Mortality (%) 
MeHg(I) 
4 120 ± 24 0.44 ± 0.04** 0.25 ± 0.02 0.64 ± 0.07 3.53 ± 0.09 0.20 ± 0.02 0 
7 103 ±10 0.41 ± 0.02 0.25 ± 0.02 0.64 ± 0.05 3.12 ± 0.49* 0.18 ± 0.03 0 
14 124 ± 35 0.40 ± 0.03 0.25 ± 0.02 0.64 ± 0.04 3.53 ± 0.36 0.19 ± 0.02 0 
29 109 ± 7 0.39 ± 0.04 0.25 ± 0.02 0.66 ± 0.04 3.37 ± 0.31 0.19 ± 0.02 0 
57 97 ± 22 0.42 ± 0.02 0.27 ± 0.02 0.68 ± 0.06 3.49 ± 0.15 0.19 ± 0.02 0 
357 121 ± 35 0.39 ± 0.01 0.25 ± 0.02 0.69 ± 0.03 3.40 ± 0.13 0.18 ± 0.01 0 
1607 38 ± 22**** 0.47 ± 0.04**** 0.26 ± 0.03 0.77 ± 0.05*** 2.87 ± 0.39*** 0.19 ± 0.02 0 
Values shown are mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 in Fisher’s LSD after 1-way ANOVA. n=5-6 rats/group 
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Actual water consumption measured in the current study (30 ± 4 ml/day) was slightly lower for all 
groups compared to the 50 ml/day reported in the literature (Table 3.2). While lead and inorganic 
mercury exposures both did not have an effect on water consumption (except at the highest and 
lethal inorganic mercury dose of 8000 µg/kg-bw/d – water consumption not shown for this group) 
compared to control, methylmercury exposure significantly and dose-dependently decreased water 
consumption (Table 3.2). Despite the lower overall water consumption and decreasing trend with 
higher methylmercury, estimated metal consumption was lower, but still close to the targeted daily 
doses for all three metal species examined in this study (Table 3.2). Limited resources prevented us 
from measuring actual lead and mercury blood levels in all treatment groups. Therefore, whole blood 
samples were analyzed for lead and methylmercury treatment groups where an adverse 
cardiovascular effect was observed plus the next lower dose without an adverse effect in order to 
determine both lowest observed adverse effects levels (LOAEL) and no-observed adverse effects 
levels (NOAEL). However, since no adverse cardiovascular effects were observed for any sub-lethal 
inorganic mercury group, the four highest doses were analyzed instead. In general, rats exposed to 
lead showed a dose-dependent increase in blood lead levels (Table 3.2). Mercury analysis revealed 
that rats exposed to 57 µg/kg-bw/d inorganic mercury had blood mercury levels that were not 
significantly different from control rats, while the three highest inorganic mercury doses resulted in 
statistically significant increases in total blood mercury (Table 3.2). In contrast, methylmercury 
exposure ≤ 357 µg/kg-bw/d showed significant (and immensely higher than inorganic mercury), 
dose-dependent increases in total mercury blood levels (Table 3.2). The exception to this dose-
dependent behavior of methylmercury was the highest dose of 1607 µg/kg-bw/d which showed a 
sharp decrease in mercury blood levels compared to the next lowest dose, but still higher than 
control rat levels (Table 3.2).  
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Table 3.2. Estimated lead and mercury exposure, target drinking water concentrations and resulting blood levels in rats after four weeks 
exposure via drinking water. 
Target dose  
(µg/kg-bw/d) 
Actual water 
consumption (ml/d) 
Nominal drinking 
water 
concentration 
(µg(ml) 
Estimated dose 
consumed (µg/kg-
bw/d) 
Actual Pb level in 
blood (µg/L) 
Actual total Hg 
level in blood 
(µg/L) 
Control 
0 33 ± 5  0 0 1.4 ± 1.2 21 ± 14 
Pb(II)      
357 33 ± 3 5 330 ± 30 17 ± 7 - 
1607 36 ± 5 21 1270 ± 680 86 ± 29*** - 
45000 38 ± 2 600 46000 ± 2600 350 ± 75**** - 
Hg(II) 
57 32 ± 4 0.8 50 ± 7 - 14 ± 1 
357 33 ± 4 5 330 ± 40 - 28 ± 10* 
2000 30 ± 3 27 1600 ± 140 - 186 ± 44**** 
4000 26 ± 3 53 2800 ± 330 - 178 ± 26**** 
MeHg(I) 
4 27 ± 4** 0.05 3 ± 0.4 - 65 ± 37 
7 29 ± 4 0.1 6 ± 1 - 193 ± 165 
14 29 ± 3* 0.2 11 ± 1 - 318 ± 146 
29 27 ± 1** 0.4 22 ± 1 - 346 ± 193 
57 28 ± 3* 0.8 45 ± 5 - 1930 ± 1316 
357 27 ± 2** 5 270 ± 15 - 14,507 ± 4631 
1607 22 ± 2**** 21 1100 ± 94 - 226 ± 69* 
Values shown are mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 in Fisher’s LSD after 1-way ANOVA. n=5-6 rats/group. 
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3.6.2 Blood and pulse pressure 
Blood pressure at 4 weeks of exposure showed differences in response compared to control rats, 
depending on both the type and dose of metal (Figure 3.1). First, lead showed a biphasic dose 
response curve with significant decreases in systolic, diastolic and pulse pressures at lower doses (7 
µg - 29 µg Pb(II)/kg-bw/d respectively; Figure 3.1). However, at higher lead exposures (1607 µg 
Pb(II)/kg-bw/d and above), rats instead had significantly higher systolic and diastolic blood pressure 
without a difference in pulse pressure compared to control rats (Figure 3.1). When we next consider 
responses to inorganic mercury, rats exposed to this metal, regardless of dose, did not show any 
significant effect on the systolic, diastolic or pulse pressures (Figure 3.1). Finally, methylmercury 
significantly increased systolic, diastolic and pulse pressures at all doses starting at 7 µg 
MeHg(I)/kg-bw/d and above for systolic and pulse pressures, but from 14 µg MeHg(I)/kg-bw/d and 
above for diastolic blood pressure (Figure 3.1). No changes were observed for heart rate after 4 
weeks of exposure (see Figure 3.2).  
Fig. 3.1. Blood and pulse pressure in rats exposed to lead (left column), inorganic mercury (middle column) and 
methylmercury (right column) for four weeks via the drinking water. Results for systolic blood pressure (A), diastolic 
blood pressure (B) and pulse pressure (C) are shown as mean± SD. For every graph, the mean value (solid 
horizontal line) for the control group ± its SD (dotted lines) are shown. *p < 0.05, **p <0.01, ***p <0.001, ****p < 
0.0001 compared to control in Fisher’s LSD posteriori test after one-way ANOVA. n=5-6 rats/group. 
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3.6.3 Cardiac function and hemodynamics 
After 4 weeks of exposure, the heart rate, end-diastolic (EDV), end-systolic (ESV) and stroke 
volumes (SV) were measured in control and metal-exposed rats. Lead exposure did not significantly 
affect heart rate, but did increase stroke volume and subsequently cardiac output at intermediate 
doses (14, 29 and 57 µg/kg-bw/d lead; Figure 3.2) where lower blood pressure was also observed 
(compare to Figure 3.1). However, at higher lead doses (above 57 µg/kg-bw/d lead), stroke volume 
and cardiac output were no longer significantly different from control values (Figure 3.2). In 
comparison, inorganic and organic mercury did not significantly affect any of the cardiac parameters 
examined (heart rate, stroke volume or cardiac output) compared to control (Figure 3.2). Finally, 
methylmercury exposure significantly decreased stroke volume at 14 µg/kg-bw/d, but not at any 
other dose and had no significant effect on heart rate or cardiac output at any dose (Figure 3.2). 
Increased SV was evident with lower, but not higher doses of lead (Figure 3.2). Both EDV and ESV 
increased at these same lower doses of lead (Supplemental Figure S8.1), with the increased SV due 
to a larger increase in EDV. Despite the changes in SV, EDV and ESV at lower lead doses, lead at 
all doses had no significant effect on ejection fraction compared to control (Supplemental Figure 
S8.1). In contrast to lead, neither inorganic mercury nor methylmercury had any significant effect on 
EDV, ESV or ejection fraction compared to control (Supplemental Figure S8.1).  
Cardiac excitation was also measured by electrocardiogram (ECG) at the end of the 4-week 
exposures to these metals. No significant changes in the PR, QRS or QT intervals after 4 weeks of 
exposure were observed for any of the metals at any dose compared to control (data not shown) 
which is consistent with the observed lack of effect on heart rate for any of these metals. 
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Fig. 3.2. Heart rate, stroke volume and cardiac output in rats exposed to lead (left column), inorganic mercury (middle 
column) and methylmercury (right column) for four weeks via the drinking water. Results for heart rate (A), stroke 
volume (B), cardiac output (C) are shown as mean ± SD. For every graph, the mean value (solid horizontal line) for 
the control group ± its SD (dotted lines) are shown. *p<0.05, **p < 0.01 compared to control in Fisher’s LSD posteriori 
test after one-way ANOVA. n=5-6 rats/group. 
Some minor changes in left ventricular free wall thickness displayed as difference between week 4 
and baseline values were noted at a few doses of some metals in this study. After 4 weeks of 
exposure to lead, left ventricular free wall thickness was not significantly different from control at 
systole, but did show a significant increase during diastole at one intermediate dose where lower 
blood pressure was also observed (14 µg Pb(II)/kg-bw/d; Figure 3.3). In contrast, inorganic mercury 
exposure at all doses failed to significantly alter free wall thickness compared to control (Figure 3.3). 
However, methylmercury exposure resulted in significantly decreased left ventricular free wall 
thickness during systole without a change during diastole at two intermediate doses (29 and 57 µg 
MeHg(I)/kg-bw/d; Figure 3.3). 
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Fig. 3.3. Change in left ventricular wall thickness from baseline to week-4 of oral exposure to lead (left column), 
inorganic mercury (middle column) and methylmercury (right column). Results are shown as mean ± SD during 
systole (A) or diastole (B): For every graph, the mean value (solid horizontal line) for the control group ± its SD 
(dotted lines) are shown. *p<0.05 compared to control in Fisher’s LSD posteriori test after one-way ANOVA. n=5-6 
rats/group. 
The carotid artery diameter, wall thickness and peak blood velocity showed different patterns of 
response after exposure to different metals (Figure 3.4) represented as the difference between week 
4 and baseline values. Lead again showed a biphasic dose-response curve for carotid artery 
diameter, carotid wall thickness and carotid blood velocity (Figure 3.4). Lead significantly increased 
the carotid artery diameter, while significantly decreasing carotid artery peak blood velocity at the 
lowest to moderate doses (4 - 357 µg/kg-bw/d lead) with a return to control values at higher doses 
(Figure 3.4). In contrast, carotid artery wall thickness was also significantly greater than control at 
the lowest lead dose to 57 µg/kg-bw/d lead, with a return to control values at higher levels (Figure 
3.4). Similar to all other blood pressure and cardiac end-points, inorganic mercury failed to show any 
significant effect on carotid artery morphology or blood flow compared to control (Figure 3.4). Finally, 
methylmercury-exposed rats had significantly greater carotid diameters at a few doses, but there 
was no clear dose-response pattern (higher at 4, 57 and 1607 µg/kg-bw/d methylmercury), but no 
significant effects on the carotid artery wall thickness or peak blood velocity were observed in 
methylmercury-exposed rats at any dose compared to control (Figure 3.4).  
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Fig. 3.4. Change in carotid artery luminal diameter, wall thickness and peak pulse-wave velocity from baseline to 
week-4 of oral exposure to lead (left column), inorganic mercury (middle column) and methylmercury (right column) 
for four weeks via the drinking water. Results for carotid luminal diameter (A), carotid wall thickness (B) and carotid 
artery pulse-wave velocity (C) are shown as mean ± SD. For every graph, the mean value (solid horizontal line) for 
the control group ± its SD (dotted lines) are shown. *p<0.05, **p <0.01, ***p <0.001 compared to control in Fisher’s 
LSD posteriori test after one-way ANOVA. n=5-6 rats/group. 
3.7 Discussion 
This study confirmed that both lead and methylmercury have adverse cardiovascular effects using 
oral exposure in a normal rat model and then determined thresholds for these adverse effects. Lead 
at doses ≥ 1607 µg/kg-bw/d and methylmercury at doses ≥ 7 µg/kg-bw/d increased blood pressure 
(15-20 mmHg) above controls, whereas inorganic mercury had no effect on any of the evaluated 
cardiovascular end-points. The observed increase in blood pressure induced by lead and 
methylmercury exposure was sufficient to turn a normotensive individual into a pre-hypertensive or 
overtly hypertensive individual. Therefore, lead and methylmercury, but not inorganic mercury, 
potentially contribute to increased cardiovascular risk but more work is needed to link our sub-
chronic exposure of 4 weeks in rats to the continuous, environmental exposures experienced by the 
human adult population.  
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3.7.1 Cardiovascular effects of lead 
In addition to the well-known neurotoxicological effects, lead also interferes with the biosynthesis of 
hemoglobin causing lead-induced anemia (Jang et al., 2011). Although red blood cells were not 
examined in this study, spleen weight was increased, which could be a consequence of removing 
damaged blood cells. Aside from anemia, blood pressure is a well-studied cardiovascular endpoint 
for lead because it is easy to examine and facilitates comparison between animals and humans 
(Navas-Acien et al., 2007; Cheng et al., 2001; Glenn et al., 2003; Nash et al., 2003). Dose-response 
curves for lead were biphasic for blood and pulse pressures. Compared to controls, low levels of 
lead decreased systolic, diastolic blood pressure and pulse pressure and dilated the carotid artery, 
which is consistent with the observed decrease in blood pressure. These physiological effects would 
also reduce the peak blood velocity in the carotid artery (Pappano, 2008). However, when blood 
pressure and arterial resistance decrease due to arterial dilation, the baroreceptor response can 
provide compensation to maintain blood pressure primarily via increased sympathetic stimulation of 
cardiac function (Pappano, 2008). Thus, it is possible, although not directly measured in the current 
study, that the observed increased stroke volume and resulting increase in cardiac output at low lead 
doses are compensatory mechanisms elicited by the baroreceptor response. An argument against a 
baroreceptor response is the fact that greater end-diastolic filling was the mechanism responsible for 
the increased stroke volume, an effect generally mediated by increased preload and blood volume 
rather than rapid compensatory mechanisms like the baroreceptor. Another possible explanation for 
higher cardiac output with low-dose lead, which is not confirmed by existing literature, is a direct 
cardio-stimulatory effect of lead at low doses. A couple of studies are available showing a direct 
acute inhibitory effects of both lead and mercury on the cardiac contractile machinery leading to 
suppressed cardiac contractility (Souza de Assis et al., 2003;Vassallo et al., 2008). Finally, the 
prolonged dilation of the carotid artery in this experiment resulted in increased wall thickness 
possibly through changes in the blood flow quality or via a direct proliferative effect of lead on the 
vascular wall. Higher lead exposure significantly increased diastolic and systolic, but not pulse 
pressures. This observation is in agreement with a large number of previous studies indicating a 
causal relationship between lead exposure and hypertension (Cheng et al., 2001; Glenn et al., 2003; 
Nash et al., 2003; Navas-Acien et al., 2007). In the current study, higher systolic and diastolic 
pressure occurred without changes in cardiac function (heart rate, stroke volume and cardiac output) 
or vascular function (carotid artery diameter, carotid wall thickness or carotid pulse wave velocity), 
compared to control. Our study did not show any changes in the electrocardiograms (ECG), while 
data from the Normative Aging Study indicated a positive association between lead body burden and 
prolonged duration of the QT interval (Cheng et al., 1998; Eum et al., 2011). The resulting 
discrepancy may be due to species differences or to exposure length/dose differences. Lead-
induced hypertension may be due to disturbances in systems involved in long-term blood pressure 
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control such as the renin-angiotensin system or kidney function (Vargas Robles et al., 2007). While 
this latter possibility would be consistent with the observed increase in diastolic filling, direct 
investigation of possible mechanisms of effects was beyond the scope of the current study. 
3.7.2 Cardiovascular effects of mercury 
The current study found that inorganic mercury did not alter any of the measured cardiovascular 
parameters, including blood pressure despite having similar total mercury blood concentrations as 
the methylmercury dosed group. The lack of blood pressure effect of inorganic mercury agrees well 
with a study by Blanco-Rivero (2011), in which rats were injected with 4.6 µg HgCl2/kg-bw (i.m.) and 
received 0.07 µg/kg-bw/d maintenance dose for 30 days. In the human population, the main 
exposure source for inorganic mercury is dental amalgam which releases elemental mercury and is 
quickly oxidized in the body to Hg(II) after inhalation (Clarkson et al., 2007). In contrast to our 
results, Goodrich et al (2013b) identified an association between decreased systolic blood pressure 
and mercury levels in the urine, which can be an indicator for inorganic mercury exposure primarily 
from dental amalgam fillings. These discrepancies between the current study, Blanco-Rivero (2011) 
and Goodrich et al (2013b) are likely due to differences in the toxicokinetics of inorganic and 
elemental mercury and the different exposure routes, namely oral, intramuscular injection and 
inhalation. In our study, which did not detect any change in the wall thickness of the carotid artery, 
we used using high-resolution ultrasound. In contrast, Aguado et al (2013) used a pressure 
myograph and found a reduced wall thickness in the thoracic aorta and mesenteric arteries of 
inorganic mercury-exposed rats. This may be due to use of different arteries or methodological 
differences. Taken together, we can conclude that inorganic mercury by itself does not exert 
cardiovascular effects, but the possibility that elemental mercury does exert cardiovascular effects. 
Similar total mercury blood levels attributed to inorganic mercury or methylmercury differed in their 
cardiovascular effects. While inorganic mercury showed no effects on the cardiovascular system, 
methylmercury caused significant effects on systolic and pulse pressures and appears to exert much 
greater cardiovascular toxicity compared to inorganic mercury at similar or lower total mercury blood 
levels. Therefore, adverse cardiovascular effects cannot be predicted by total blood mercury level 
alone. Methylmercury doses closer to the higher end of our dosing range 500 µg/kg-bw/d 
methylmercury by gavage for 28 days (Wakita, 1987), 100 µg MeHg/kg-bw for 100 days (Grotto et 
al., 2009) or a diet high in MeHg-contaminated fish to simulate human consumption fed to rats for 12 
weeks (Grotto et al., 2011) increased blood pressure either latently (significant only weeks after the 
exposure period) or after a longer exposure duration compared to the current study. We were able to 
observe significant increases in systolic blood pressure at much lower doses (starting at 7 µg/kg-
bw/d methylmercury), which is most likely due to the more sensitive method of blood pressure 
measurement used in the current study (intravascular, direct blood pressure method) compared to 
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the previous studies where a much less sensitive and less reliable method was used (tail cuff 
plethysmography). Although no significant cardiac effect was observed at any methylmercury dose 
in the current study, a significant vascular effect (increased carotid artery diameter) was observed at 
an even lower dose of 4 µg/kg-bw/d methylmercury than the blood pressure effect. However, the 
direct effect of increased carotid diameter would be to reduce peripheral resistance and decrease 
blood pressure while the opposite effect was observed in this study. The effect of methylmercury on 
the carotid artery diameter was inconsistent for all doses. Therefore the blood pressure values were 
taken as more reliable and used for derivation of threshold of effect below. In contrast to inorganic 
mercury exposure, methylmercury exposure increases blood pressure but the mechanism is unclear.   
3.7.3 Blood metal levels and thresholds for adverse cardiovascular effect of lead and 
mercury 
In the current study, control rat blood lead levels were 1 µg/L (or 0.1 µg/dL), which is lower than the 
level of 13.4 µg/L (or 1.34 µg/dL) in the general population (Health Canada, 2013). Exposures to 357 
and 1607 µg Pb(II)/kg-bw/d produced blood lead levels of 2 ± 0.7 and 9 ± 3 µg/dL respectively, 
which are below the lead guidance value of 10 µg/dL (Healey et al., 2010), while the highest 
exposure group (at 45,000 µg Pb(II)/kg-bw/d) produced levels comparable to occupational 
exposures (≥ 25 µg/dL) (CDC, 2011) to lead. Thus, our range of lead doses is suitable for 
determining if current thresholds for effects are sufficiently protective. The mercury reference values 
of 20 – 100 µg/L (Statistics Canada, 2008) were not exceeded by the control rats (21 ± 14 µg/L) and 
lowest dose groups of both mercury species, i.e. 57 µg Hg(II)/kg-bw/d (14 ± 1 µg/L) and 4 µg 
MeHg(I)/kg-bw/d (65 ± 37 µg/L). Inorganic mercury showed a slow dose-dependent increase in 
blood levels, while the highest dose of methylmercury showed a sharp decrease in total mercury 
levels probably due to reduced water consumption, weight loss and signs of toxicity.  
As increased blood pressure is the most important risk factor for cardiovascular diseases, systolic 
blood pressure was selected as critical end-point. NOAELs and LOAELs were directly derived from 
the study results. NOAEL and LOAEL for lead were 57 µg/kg-bw/d and 357 µg/kg-bw/d, respectively. 
As inorganic mercury did not result in any cardiovascular effect, it was not possible to derive a 
LOAEL. The NOAEL was determined at 4000 µg/kg-bw/d. For methylmercury, a NOAEL of 4 µg/kg-
bw/d and a LOAEL of 7 µg/kg-bw/d were derived. An alternative to the NOAEL-LOAEL approach is 
the benchmark dose (BMD) approach. The BMDL10s calculated for lead, inorganic mercury and 
methylmercury were 1.1, 1.3 and 1.0 µg/kg-bw/d, respectively. The European Food Safety Authority 
(EFSA, 2012b) published a BMDL01 for lead and cardiovascular effects of 1.5 µg/kg-bw/d. Although 
these estimates are remarkably close, discrepancies can be explained by the use of different 
datasets and species differences.  
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A large number of studies in humans exists investigating human exposure to low levels of 
methylmercury on a chronic basis, largely through the consumption of fish and seafood. Several 
epidemiological studies show a positive association between the intake of sea mammals, fish and 
seafood and blood pressure increase. Comparing blood pressure values of Danes (blood mercury of 
2.2 µg/L) and Greenlanders (blood mercury of 10.8 µg/L) showed that Greenlanders following a 
traditional diet had higher blood and pulse pressures with increasing mercury blood levels (Pedersen 
et al., 2005) which is strikingly similar to our observations with methylmercury in rats. A study in the 
Brazilian Amazon (Fillion et al., 2006) showed a positive relation between mercury hair levels of 17.8 
µg/g (we calculated: blood Hg 71.2 µg/L based on conversion ratios in Clarkson (2007)) and higher 
blood pressure, although the overall prevalence of hypertension was low. Valera et al carried out a 
number of studies evaluating different population groups, such as Inuit, French Polynesians, whose 
traditional diet is rich in fish and seafood. In Nunavik Inuits a positive relation between blood mercury 
(50 – 133 µg/L) and systolic blood and pulse pressure was observed (Valera et al., 2008; 2009). 
These findings are in contrast to the results from studies in French Polynesians (teenager: blood Hg 
8 µg/L; adults: blood Hg 15 µg/L) (Valera et al., 2011b) or in Cree adults (blood Hg 15 µg/L) (Valera 
et al., 2011a) which did not show any significant relationship to blood pressure. These blood levels 
are similar to the mercury blood level of 65 µg/L from the lowest methylmercury dose in our rat 
study, which did not detect a significant change in blood pressure compared to control. However, the 
next dose of 7 µg/kg-bw/d methylmercury resulted in higher mercury blood level at 193 µg/L and an 
increase in blood pressure, which is similar to the highest end of the range reported in the above 
human studies. In human studies, confounding factors, including consumption of environmental 
pollutants, beneficial nutrients as well as co-existence of diseases like obesity, diabetes, cigarette 
smoking or dental health, can potentially modulate cardiovascular function. Therefore, considering 
these confounding factors, the fact that the methylmercury levels producing significant increases in 
blood pressure in rats in the current study are close to the observed human range reporting 
associations provides high confidence in these results.  
3.7.4 Strengths and limitations 
The strength of our study is the use of highly sensitive imaging and blood pressure measurement 
techniques for the examination of a broad range of cardiovascular end-points, including blood 
pressure as an important biomarker in human and animal studies with clear clinical benchmarks for 
health consequences in humans (WHO/ISH, 2003), and better characterization of vascular or 
cardiac effects. Additionally, the high number of metal doses, allowed for better identification of 
thresholds for adverse cardiovascular effects. Study limitations were the short exposure duration (4 
weeks) in comparison to long-term human exposure, the use of a male only rat cohort and the small 
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sample size per group. However, despite the small group size, the higher sensitivity of our 
measurement methods allowed us to detect changes at lower thresholds than reported previously.  
3.8 Conclusions 
To our knowledge, this was the first study to investigate cardiovascular effects of lead and mercury 
exposure using high resolution imaging techniques (high-resolution ultrasound) along with direct, 
intravascular blood pressure measurements in rats. We confirmed the positive association between 
oral lead exposure and higher blood pressure. However, of note was the clear biphasic dose-
response to lead, with lower doses decreasing blood pressure and higher doses causing sufficient 
increase in blood pressure to make an individual hypertensive (15-20 mmHg increase). Low lead 
doses seemed to have a greater effect on the vasculature where vasodilation lowered blood 
pressure. Lead is known to substitute for calcium ions (Ballatori, 2002), thereby blocking smooth 
muscle calcium channels and offering a potential explanation for the observed vasodilation with low-
dose lead. In contrast, direct effects of low-dose lead on cardiac calcium channels which would 
impair cardiac contractility were not detected since instead an increase in stroke volume was 
observed in the current study. The observed increase in stroke volume with low-dose lead would be 
consistent with either the decreased afterload or a baroreceptor response to vasodilation. Then, at 
higher doses of lead in this study, blood pressure increased despite a return to control levels of 
cardiac function. While we do not know the mechanism(s) explaining how high-dose lead increased 
blood pressure, it likely relates to effects on other blood pressure regulating systems that function 
independent of cardiac or neural effects, such as increased renin-angiotensin-aldosterone system 
activation, vasoconstriction from angiotensin II and/or increased blood volume. Elucidating 
mechanisms of metal effects in the cardiovascular system is the focus of future investigations. 
In this study, we also shed light on the relationship between mercury species and cardiovascular 
health. While inorganic mercury did not affect cardiovascular health in our study and therefore 
cannot be used as a surrogate for environmental mercury exposure, methylmercury clearly poses a 
risk factor for hypertension and should be considered in assessment of methylmercury risk to human 
health. In the future, more studies are needed to elucidate mechanisms by which adverse 
cardiovascular effects of lead and mercury occur as well as examining the influence of nutritional 
factors or co-existence of disease states that may further increase the cardiovascular risk of these 
metals. 
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4 COMBINED EXPOSURE TO LEAD, INORGANIC MERCURY AND 
METHYLMERCURY SHOWS DEVIATION FROM ADDITIVITY FOR 
CARDIOVASCULAR TOXICITY IN RATS 
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4.2 Preface 
The human population is generally exposed to mixtures of Pb(II), Hg(II) and MeHg(I). However, due 
to a lack of data on the relevant mixtures, risk assessments are often a challenge. For this case, we 
have data available on cardiovascular effects from single exposures to Pb(II), Hg(II) and MeHg(I) 
and their mixtures. This allowed us to directly observe how combined exposures affected the 
cardiovascular system but also to compare them to the single exposures.  
Published as Wildemann, T.M.; Weber, L.P.; Siciliano, S.D. (2014) Combined exposure to lead, 
inorganic mercury and methylmercury shows deviation from additivity for cardiovascular toxicity in 
rats, Journal of Applied Toxicology, (in press) doi 10.1002/jat.3092 
4.3 Abstract 
Environmental exposure to metal mixtures in the human population is common. Mixture risk 
assessments are often challenging due to a lack of suitable data on the relevant mixture. A growing 
number of studies show an association between lead or mercury exposure and cardiovascular 
effects. We investigated the cardiovascular effects of single metal exposure or co-exposure to 
methylmercury, inorganic mercury and lead. Male Wistar rats received four different metal mixtures 
for 28 days through the drinking water. The ratios of the metals were based on reference and 
environmental exposure values. Blood and pulse pressure, cardiac output and electrical activity of 
the heart were selected as end-points. While exposure to only MeHg(I) increased systolic blood 
pressure and decreased cardiac output, the effects were reversed with combined exposures 
(antagonism). In contrast to these effects, combined exposures negatively affected the electrical 
activity of the heart (synergism). Thus, it appears that estimates of blood total Hg levels need to be 
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paired with estimates of what species of mercury dominate exposure as well as whether lead co-
exposure is present to link total blood Hg levels to cardiovascular effects. Based on current human 
exposure data and our results, there may be increased risk of cardiac events as a result of combined 
exposures to Hg(II), MeHg(I) and Pb(II). This increased risk needs to be clarified by analyzing lead 
and Hg exposure data in relation to cardiac electrical activity in epidemiological studies. 
4.4 Introduction 
Metals occur ubiquitously in the environment due to natural and anthropogenic sources although 
environmental concentrations differ depending on the geographical areas. In contrast to organic 
chemicals, metals have unique properties, such as not being degradable over time or destroyable 
(U.S. EPA, 2007). Metals are generally found as mixtures with other metals. Therefore, the United 
States Environmental Protection Agency (U.S. EPA, 1986) recommends assessing the risks 
originating from combined metal exposures by calculating a hazard index (HI; Eq. 1):  
HI = E1/AL1 + E2/AL2 + …+ Ei/ALi 
The hazard index is defined by the sum of ratios of the exposure (E) to the maximum acceptable 
level (AL) for i
th
 toxicants. Depending on the number of end-points, in which the risk assessor is 
interested, more than one HI can be determined.  
The human population is generally exposed to a varying number of metals, at the same time leading 
to chronic, low level exposures. Among the metals of concern, lead and mercury species are 
important environmental pollutants. Lead (Pb(II)) exposure mainly occurs through the drinking water 
and food (ATSDR, 2007; EFSA, 2012b; Health Canada, 2013) with increased absorption likely 
occurring in children and elderly due to their age and nutrition status. For mercury, exposure occurs 
primarily through dental amalgam or food. Dental amalgam contains about 50% mercury 
(Richardson and Allan, 1996), and once the fillings are placed in the patient’s teeth, mercury vapor 
will be continuously released and inhaled by the person. The inhaled mercury vapor is able to easily 
penetrate the blood-brain barrier and oxidation to inorganic mercury rapidly occurs in a number of 
different tissues and organs, such as brain or kidneys (Clarkson et al., 2007). In contrast, to dental 
amalgams, where final exposure is to Hg(II), food exposure to mercury is primarily via 
methylmercury (MeHg(I)). Due to its lipophilic properties, MeHg(I) has a high absorption rate from 
the gut and is distributed throughout the entire body. It can be incorporated into proteins mimicking 
the amino acid methionine (Clarkson et al., 2007; Ballatori, 2002) or can be converted into inorganic 
mercury.  
Traditionally, lead and mercury are considered to be neurotoxicants with the developing central 
nervous system as the most sensitive end-point (Ekino et al., 2007; Bakir et al., 1980; Finkelstein et 
al., 1998; Sanders et al., 2009). However, Pb(II) or Hg exposure is also associated with 
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cardiovascular effects. Large epidemiological studies, e.g. the National Health and Nutrition 
Examination Survey (NHANES), have provided enough evidence to consider the association 
between Pb(II) exposure and increased blood pressure as causal (Navas-Acien et al., 2007; Glenn 
et al., 2003) in every major population group included in NHANES. Hypertension is considered to be 
the most important risk factor for cardiovascular diseases. These cardiovascular diseases are 
responsible for the majority of deaths worldwide (WHO/ISH, 2003). Laboratory based experiments 
found that rats exposed to Pb(II) through the drinking water (Skoczynska et al., 2014) had impaired 
heart function with a decreased cardiac ejection fraction. Epidemiological studies investigating Hg 
exposure and cardiovascular effects have produced contradicting results. On one hand, results from 
human studies (Bautista et al., 2009; Valera et al., 2009; Pedersen et al., 2005) demonstrated a 
relation between Hg exposure and hypertension and pulse pressure. On the other hand, a number of 
epidemiological studies (Vupputuri et al., 2005; Johansson et al., 2002; Mozaffarian et al., 2012; 
Valera et al., 2011a) could not show an association between Hg exposure and hypertension or 
cardiovascular diseases in general (Mozaffarian et al., 2011). 
Governmental agencies have been considering hypertension as an important end-point for adults for 
Pb(II) or Hg exposure. The European Food Safety Authority (EFSA, 2012b) deemed the available 
body of literature for Pb(II) as sufficient to suggest a 95
th
 percentile lower confidence limit of the 
benchmark dose of 1% extra risk (BMDL01) for systolic blood pressure in adults. A BMDL01 of 1.5 
µg/kg-bw/d was determined as critical concentration. Due to the limited amount of studies on 
cardiovascular effects, the Joint FAO/WHO Expert Committee on Food Additives (FAO/WHO, 2004) 
based the tolerable weekly intakes (TWIs) for Hg(II) and MeHg(I) on developmental neurotoxicity 
with 4 µg/kg-bw (0.57 µg/kg-bw/d) and 1.6 µg/kg-bw (0.23 µg/kg-bw/d) respectively.  
Generally, human exposure to Pb(II) and Hg through the environment is below the established 
reference values for a single exposure. In the European Union, environmental exposures were 
estimated as 0.039 µg/kg-bw/d for MeHg(I), 0.08 µg/kg-bw/d for Hg(II) (EFSA, 2012a) and 0.68 
µg/kg-bw/d for Pb(II) (EFSA, 2012b). Calculating the HI based on environmental exposure and 
reference values (Eq. 2), a HI of 0.7 is obtained. 
HI = EMeHg(I)/ALMeHg(I) + EHg(II)/ALHg(II) + EPb(II)/ALPb(II) = 0.039/0.23 + 0.08/0.57 + 0.68/1.5 = 0.7 
Hence, no adverse health effect is expected and the general population is considered to be 
protected. However, these estimations are based on the assumption that there is no deviation from 
additivity between toxicant effects and thus, there is considerable uncertainty associated with this HI. 
Although humans are generally exposed to more than one chemical at the same time, data for 
combined exposures are scarce, which renders risk assessment of chemical mixtures challenging. 
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Additional uncertainty is inserted by using a toxicity end-point, e.g. developmental effects, which 
might be of minor importance for the susceptible group, such as elderly. To investigate 
cardiovascular effects of combined exposure to Pb(II), Hg(II) and MeHg(I), rats were exposed orally 
to four different mixtures containing these metals for four weeks. The concentration ratios were 
based on the ratios among published reference values or environmental exposure values. 
Cardiovascular end-points, such as blood pressure, cardiac output and electrical conductivity of the 
heart were selected considering that adults and in particular the elderly population might have an 
increased risk of cardiovascular diseases due to chronic Pb(II) and Hg exposure. We hypothesized 
that combined exposure to lead acetate, mercury chloride and mono-methylmercury aggravates 
adverse effects on the cardiovascular system due to synergistic effects.  
4.5 Materials and methods 
4.5.1 Animals 
Male rats (Wistar strain, 250 - 300 g) were obtained from Charles River Laboratories, Senneville, 
QC, Canada. The animals were housed in single cages, at 22°C room temperature and a 12:12h-
light dark cycle with access to standard rat chow ad libitum at the Western College of Veterinary 
Medicine at the University of Saskatchewan (Saskatoon, SK, Canada). The experiment was 
approved by the University of Saskatchewan’s Animal Research Ethics Board and carried out 
according to the guidelines of the Canadian Council on Animal Care (CCAC).  
After one week of acclimatization, the experiment was initiated. Rats were exposed (n = 5 per group) 
for four weeks to either lead acetate (Pb(II); 357 or 1607 µg/kg-bw/d), mercury chloride (Hg(II); 57 or 
357 µg/kg-bw/d) or mono-methylmercury chloride (MeHg(I); 29 or 357 µg/kg-bw/d) or a mixture of all 
three metals via the drinking water (tap water with 0.2% nitric acid). The dose of single metal 
exposure was comparable to the dose in the mixtures. The control group (n = 6) received tap water 
with 0.2% nitric acid. All chemicals were ordered from Sigma-Aldrich (Oakville, ON, Canada). 
4.5.2 Calculation for combined exposures 
The classical method to carry out experiments with combined exposures is to use a factorial design. 
However, these types of experiments require a large number of treatment groups and hence animals 
(Casey et al., 2006). Adhering to the principles of the 3Rs (Reducing, Refining, Replacing), the fixed-
ratio ray design (Brunden and Vidmar, 1989) was instead applied for this study (Table 4.1). One 
fixed-ratio ray (R) was based on the ratio between reference levels for methylmercury, inorganic 
mercury and Pb(II). A second fixed-ratio ray (10R) was also based on the reference levels ratio but 
doses were multiplied by 10. A third fixed-ratio ray (E) was based on environmental exposure values 
for methylmercury, inorganic mercury and Pb(II). The fourth fixed-ratio (10E) was again based on 
environmental exposure values multiplied by 10.  
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The European Food Safety Authority (EFSA, 2012b) published a BMDL01 for Pb(II) and systolic 
blood pressure as end-point of 1.5 µg/kg-bw/d. The Joint FAO/WHO Expert Committee on Food 
Additives (FAO/WHO, 2004) set a tolerable weekly intake (TWI) of 1.6 µg/kg-bw for methylmercury 
which would equal 0.23 µg/kg-bw per day. JECFA (FAO/WHO, 2011; 2004) also established a TWI 
of 4 µg/kg-bw for inorganic mercury corresponding to 0.57 µg/kg-bw per day. Both TWIs were 
confirmed by EFSA. Based on these reference values the ratio is MeHg(I) : Hg(II) : Pb(II) = 1 : 3 : 7 
(Table 4.1). As MeHg(I) is the most toxic of these metals, the MeHg(I) dose was considered to be 
the starting point. In a previous study (Wildemann et al., 2015) a dose of 29 µg/kg-bw/d increased 
systolic blood pressure. Therefore, this dose was used for MeHg(I). The first fixed-ratio ray (R) for 
reference values applied 29 µg MeHg(I)/kg-bw/d, 87 µg Hg(II)/kg-bw/d and 203 µg Pb(II)/kg-bw/d. 
For the second fixed-ratio ray (10R) based on reference values, the doses were multiplied by 10. 
Hence, the doses were 290 µg MeHg(I)/kg-bw/d, 870 µg Hg(II)/kg-bw/d and 2030 µg Pb(II)/kg-bw/d 
(Table 4.1). The same approach was used for fixed-ratio rays based on environmental exposures. 
EFSA estimated European environmental exposure at 0.039 µg/kg-bw/d for MeHg(I), 0.08 µg/kg-
bw/d for Hg(II) (EFSA, 2012a) and 0.68 µg/kg-bw/d for Pb(II) (EFSA, 2012b). This provides a ratio of 
MeHg(I) : Hg(II) : Pb(II) = 1 : 2 : 17. As starting dose 29 µg MeHg(I)/kg-bw/d was used again. The 
third fixed-ratio ray (E) based on environmental exposure applied the following ratio MeHg(I) : Hg(II) 
: Pb(II) = 29: 58 : 493 µg/kg-bw/d. To calculate the doses for the fourth fixed-ratio ray (10E), the 
doses from ray 3 (E) were multiplied by 10 resulting in 290 µg MeHg(I)/kg-bw/d, 580 µg Hg(II)/kg-
bw/d and 4930 µg Pb(II)/kg-bw/d (Table 4.1). 
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Table 4.1. Ratios for combined exposures 
 
 Group label MeHg(I) 
(µg/kg-bw/d) 
Hg(II) 
(µg/kg-bw/d) 
Pb(II) 
(µg/kg-bw/d) 
Reference values 
Ratio  
R 0.23 
1 
0.57 
3 
1.5 
7 
Environmental exposure values 
Ratio  
E 0.039 
1 
0.08 
2 
0.68 
17 
Experimental ratios     
Reference values (I) R 29 87 203 
Reference values (II) 10R 290 870 2030 
Environmental exposure values (I) E 29 58 493 
Environmental exposure values (II) 10E 290 580 4930 
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4.5.3 High-resolution cardiovascular ultrasound, arterial blood pressure and 
electrocardiography 
In the anesthetized rats, heart function, blood pressure and cardiac conductivity was measured at 
baseline and after four weeks of exposure. A high-resolution B-mode ultrasound (Visualsonics Vevo 
770®, Toronto, ON, Canada) was used to measure the stroke volume according to methods 
previously used in this laboratory (Wildemann et al., 2015). For stroke volume, in systole and 
diastole the length of the left ventricle was measured in triplicate in parasternal long axis view in B-
Mode and three cross-sectional areas (A1, A2, A3) in parasternal short axis view. Applying 
Simpson’s rule (Boon, 2011), these measurements were used to calculate left ventricular volumes at 
end-systole (ESV) and end-diastole (EDV). The stroke volume (SV) was calculated as the difference 
between EDV and ESV, while cardiac output was calculated as the product of heart rate (HR) and 
SV.  
After four weeks of exposure and a 24 h recovery after the last ultrasound examination, intravascular 
blood pressure in the femoral artery, heart rate and a Lead-(II)-electrocardiogram (ECG) were 
measured using PowerLab with LabChart software (ADInstruments, Colorado Springs, CO, USA) as 
the data acquisition system according to previously established methods in this laboratory 
(Wildemann et al., 2015). All measurements were recorded for 10 minutes and averaged.  
4.5.4 Blood analysis 
After four weeks of exposure, whole blood (5-9 samples/dose) were collected and sent for analysis 
to the Prairie Diagnostic Services Inc., Western College of Veterinary Medicine, University of 
Saskatchewan (Saskatoon, SK, Canada). In addition to the blood samples, deionized ultra-filtered 
water, feed, tap water and prepared drinking water of controls were analyzed for quality control. The 
samples were prepared through a nitric acid (69-70%) digestion in a Mars Microwave Accelerated 
Reaction System (CEM, Matthews, NC, USA). The prepared samples were analyzed with 
Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) (Thermo Scientific X Series 2, Waltham, 
MA, USA).  
4.5.5 Statistical analysis 
Results are presented as mean ± standard deviation (SD). Normality and homogeneity of variance of 
the data were evaluated using Kolmogorov-Smirnov and Bartlett’s tests. Unpaired student’s t-tests 
were carried out between control and exposure groups, and among exposure groups 
(GraphPadPrism, GraphPad Software, Inc., San Diego, CA, USA). Exposure groups consisted of 
one-metal exposure (MeHg(I), Hg(II), Pb(II)) or three-metal exposures (MeHg(I), Hg(II) and Pb(II)). A 
p<0.05 was considered significant. 
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4.6 Results 
4.6.1 Growth performance and blood analysis 
There were no obvious signs of gross toxicity or mortalities after exposure to single or metal 
mixtures after four weeks of oral exposure. Exposures to one metal (29 MeHg(I), 57 Hg(II), 357 
Pb(II) µg/kg-bw/d) were chosen in such a way that they are comparable to the corresponding doses 
in the metal mixtures (Table 4.1). The ratios for the metal mixtures were based on ratios for human 
reference values (1:3:7 MeHg(I):Hg(II):Pb(II)) and environmental exposures (1:2:17 
MeHg(I):Hg(II):Pb(II)). Methylmercury was selected as the starting point for the calculation of the 
ratios because it is more toxic than Hg(II) and Pb(II). The MeHg(I) dose of 29 µg/kg-bw/d as a single 
toxicant significantly increased systolic (129 ± 9 mmHg) and diastolic blood pressure (83 ± 9 mmHg) 
in comparison to control (104 ± 5/66 ± 6 mmHg) (Wildemann et al., 2015). Doses for Hg(II) and 
Pb(II) were then calculated based on the ratios of human reference values and environmental 
exposures. No significant changes were identified in bodyweight gain, or organ weight in relation to 
total bodyweight in any treatment group after four weeks compared to control (Table 4.2).  
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Table 4.2. Organ weights in rats after four weeks oral exposure to mixtures of metals in drinking water 
Experimental dose ratio 
(µg/kg-bw/d) 
Δ Bodyweight (g) Brain/body 
weight (%) 
Heart/body 
weight (%) 
Kidneys/body 
weight (%) 
Liver/body 
weight (%) 
Spleen/body 
weight (%) 
Control       
0 134 ± 26 0.35 ± 0.07 0.27 ± 0.03 0.68 ± 0.05 3.74 ± 0.34 0.21 ± 0.02 
Mixture experiment 
R (29 : 87 : 203) 114 ± 23 0.40 ± 0.06 0.26 ± 0.02 0.68 ± 0.03 3.56 ± 0.12 0.21 ± 0.03 
10R (290 : 870 : 2030) 108 ± 11 0.41 ± 0.03 0.27 ± 0.03 0.64 ± 0.27 3.05 ± 1.27 0.22 ± 0.06 
E (29 : 58 : 493) 115 ± 18 0.34 ± 0.08 0.27 ± 0.02 0.67 ± 0.10 3.48 ± 0.33 0.20 ± 0.02 
10E (290 : 580 : 4930) 139 ± 19 0.33 ± 0.07 0.26 ± 0.02 0.71 ± 0.06 3.71 ± 0.21 0.21 ± 0.04 
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Single exposure to MeHg(I) decreased water consumption (p<0.05), while exposures to Hg(II), Pb(II) 
or mixtures had no effect on water consumption (Table 4.3). Furthermore, exposure to only MeHg(I) 
resulted in lower total blood Hg levels than when MeHg(I) was part of a mixture of metals. For 
example, exposure to 29 µg/kg-bw/d MeHg(I) resulted in total Hg blood levels of 346 ± 193 µg/L 
(Table 4.3). Whereas when MeHg(I) was part of a mixture at the same dose level, i.e. 29 µg/kg-bw/d, 
total Hg blood levels increased (p<0.05). As the contribution of Hg(II) to blood levels can be 
considered negligible as the low Hg(II) dose levels by itself resulted in 15 ± 1 µg/L mercury in blood, 
it can be assumed that MeHg(I) availability is increased in combination with Hg(II) exposure but not 
because of Pb(II) exposure. This mixture dependence was also dependent on the ratios, with the 
increase induced by the regulatory ratio 290% greater than that for the environmental ratio which 
increased total Hg blood levels by only 200%. Hg(II) was higher and Pb was lower in the regulatory 
ratio mixture compared to the environmental ratio and the increase in total blood Hg levels was 
associated with the regulatory ratio. The total Hg blood levels were well above the human mercury 
reference values of 20-100 µg/L (Statistics Canada, 2008) for a Hg(II) dose of 357 µg/kg-bw/d, 
MeHg(I) doses of 29 and 357 µg/kg-bw/d and all mixtures (Table 4.3). 
In contrast to MeHg(I), mixtures decreased (p<0.05) Pb(II) blood levels from 86 ± 29 µg/L at a dose 
of 1607 µg/kg-bw/d to 50 ±18 µg/L at 2030 µg/kg-bw/d in the higher regulatory ratio (290:870:2030 
MeHg(I):Hg(II):Pb(II); µg/kg-bw/d) (Table 4.3). Furthermore, the blood Pb(II) levels also depended on 
the ratios (p<0.05), with the lower environmental ratio (29:58:493 MeHg(I):Hg(II):Pb(II); µg/kg-bw/d) 
(15 ± 5 µg/L) decreasing the blood levels by ca. 12 % and the lower regulatory ratio (29:87:203 
MeHg(I):Hg(II):Pb(II); µg/kg-bw/d) by 47%. The blood Pb(II) levels from the lower Pb(II) doses, i.e. 
357 µg/kg-bw/d for Pb(II) only and 203 and 493 µg/kg-bw/d as part of the mixture, produced blood 
levels of Pb(II) comparable to the Pb guidance value of 10 µg/dl (Healey et al., 2010). The higher 
Pb(II) doses of 1607 µg/kg-bw/d for Pb(II) exposure and 2030 and 4930 µg/kg-bw/d within mixtures 
resulted in blood Pb(II) levels (50 – 86 µg/L) comparable to values found in workers exposed to lead 
in an occupational setting (Table 4.3).  
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Table 4.3. Exposure and blood analysis for lead and total mercury 
Anticipated ratio (µg/kg-
bw/d) 
Water 
consumption 
ml/d 
Nominal drinking 
water concentration 
(µg/ml) 
Estimated dose 
consumed 
(µg/kg-bw/d) 
Blood Pb(II) levels 
(µg/L) 
Total blood Hg 
levels (µg/L) 
Control 
0 37 ± 6 0 0 1.4 ± 1.2 21 ± 14 
MeHg(I)      
29  27 ± 1** 0.4 22 ± 1 - 346 ± 193 
357 27 ± 2** 5 270 ± 15 - 14,507 ± 4631 
Hg(II)      
57 32 ± 4 0.8 51 ± 7 - 14 ± 1 
357 33 ± 4 5 330 ± 40 - 28 ± 10 
Pb(II)      
357 33 ± 3 5 330 ± 30 17 ± 7 - 
1607 36 ± 5 21 1270 ± 680 86 ± 29 - 
Mixture study 
R (29 : 87 : 203) 31 ± 4 0.4 : 1 : 3 25 : 62 : 186 9 ± 3 1000 ± 660* 
10R (290 : 870 : 2030) 32 ± 3 4 : 11 : 27 256 : 704 : 1728 50 ± 18 15,500 ± 4800 
E (29 : 58 : 493) 33 ± 3 0.4 : 0.7 : 7 25 : 46 : 462 15 ± 5 680 ± 190* 
10E (290 : 580 : 4930) 30 ± 2 4 : 8 : 66 240 : 480 : 3960 80 ± 24 11,200 ± 4100 
Ratios are presented as MeHg(I):Hg(II):Pb(II); results are presented as the mean ± SD. *p=0.01-0.05, **p=0.001-0.01, ***p=0.001-0.0001, ****p<0.0001 
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4.6.2 Blood and pulse pressure 
Higher doses of MeHg(I) increased blood and pulse pressure, while mixtures reduced the values to 
control level. At lower exposure levels (Figure 4.1A), MeHg(I) at a dose of 29 µg/kg-bw/d increased 
(p<0.05) systolic blood pressure compared to Hg(II) alone. In contrast, combinations of metals at 
higher environmental exposure ratios of (290:580:4930 MeHg(I):Hg(II):Pb(II); µg/kg-bw/d), lowered 
(p<0.05) systolic and diastolic blood pressure as well as pulse pressure (Figure 4.1B) to control 
levels. This decrease in blood and pulse pressure appeared to be linked to differential responses of 
the blood and pulse pressure to mixtures in comparison to single exposures to MeHg(I), Hg(II) and 
Pb(II). For example, at both low (29 µg/kg-bw/d) and high (357 µg/kg-bw/d) doses, exposure to only 
MeHg(I) increased (p<0.05) systolic blood pressure (129 ± 9 and 131 ± 5 mmHg respectively) 
compared to Hg(II) alone doses (116 ± 8mmHg) and the control group (117 ± 11 mmHg). Pulse 
pressure was lower (p<0.05) in Hg(II) (39 ± 3 mmHg) and Pb(II) (39 ± 5 mmHg) alone exposed 
animals compared to MeHg(I) (46 ± 3 mmHg) at the higher doses. 
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Fig. 4.1. Blood pressure and pulse pressure. Results are shown after four weeks of exposure. Row A: systolic and 
diastolic blood pressure and pulse pressure for one-metal exposure of methylmercury (29 µg/kg-bw/d), Hg(II) (57 
µg/kg-bw/d), Pb(II) (357 µg/kg-bw/d) and reference value ratio (MeHg(I):Hg(II): Pb(II) = 29:87:203) and environmental 
exposure ratio (MeHg(I):Hg(II): Pb(II) = 29:58:493); row B: systolic and diastolic blood pressure and pulse pressure 
for one-metal exposure of methylmercury (357 µg/kg-bw/d), Hg(II) (357 µg/kg-bw/d), Pb(II) (1607 µg/kg-bw/d) and 
reference value ratio (MeHg(I):Hg(II): Pb(II) = 290:870:2030) and environmental exposure ratio (MeHg(I):Hg(II): Pb(II)  
= 290:580:4930); unpaired student’s t-test *p = 0.01-0.05, **p = 0.001 – 0.01 
 
4.6.3 Heart function 
Similar to the effects observed for blood and pulse pressure, metal mixtures reversed the adverse 
effects on heart function associated with single metal exposure to control level (Figure 4.2). Cardiac 
output responded differently to single metal exposure compared to mixtures. Exposure at the high 
MeHg(I) (357 µg/kg-bw/d) alone showed a 40% lower cardiac output than the higher reference value 
ratios (290:870:2030 MeHg(I):Hg(II):Pb(II); µg/kg-bw/d) (39 ± 12 ml/min) reversing this effect to 
control levels. 
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Fig. 4.2. Heart function as indicated by heart rate, stroke volume and cardiac output. Results are shown after four 
weeks of exposure. Row A: heart rate, stroke volume and cardiac output for one-metal exposure of methylmercury 
(29 µg/kg-bw/d), Hg(II) (57 µg/kg-bw/d), Pb(II) (357 µg/kg-bw/d) and reference value ratio (MeHg(I):Hg(II): Pb(II) = 
29:87:203) and environmental exposure ratio (MeHg(I):Hg(II): Pb(II) = 29:58:493); row B heart rate, stroke volume 
and cardiac output for one-metal exposure of methylmercury (357 µg/kg-bw/d), Hg(II) (357 µg/kg-bw/d), Pb(II) (1607 
µg/kg-bw/d) and reference value ratio (MeHg(I):Hg(II): Pb(II) = 290:870:2030) and environmental exposure ratio 
(MeHg(I):Hg(II): Pb(II) = 290:580:4930); unpaired student’s t-test *p = 0.01-0.05, **p = 0.001 – 0.01 
4.6.4 Cardiac electrical conductivity 
In contrast to blood and pulse pressure (Figure 4.1) and heart function (Figure 4.2), mixtures 
produced an adverse effect on cardiac electrical conductivity while single metal exposures were 
comparable to control levels (Figure 4.3). Ratios based on human reference values (29:87:203 and 
290:870:2030 MeHg(I):Hg(II):Pb(II); µg/kg-bw/d) increased (p<0.05) the duration of the QRS interval 
in comparison to single metal exposures and the environmental ratios. As an example, the highest 
increase of 40% was observed between exposure to Hg(II) and the reference value ratios. At the 
higher reference value ratio (290:870:2030 MeHg(I):Hg(II):Pb(II); µg/kg-bw/d), the duration of the QT 
interval was increased by about 20% compared to Pb(II) alone and controls (p<0.05). In contrast, the 
PR interval followed the previous trend where single metal exposures produced a prolonged PR 
interval, while mixtures normalized this adverse effect. For example, exposure to lower levels of 
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Hg(II) (57 µg/kg-bw/d) alone prolonged the PR interval in comparison to MeHg(I) (29 µg/kg-bw/d) 
alone and lower dose mixtures (29:87:203 and 29:58:493 MeHg(I):Hg(II):Pb(II); µg/kg-bw/d).  
 
Fig. 4.3. Electrical conductivity of the heart by electrocardiogram (ECG). Results are shown after four weeks of 
exposure. Row A: QT, QRS and QT intervals for one-metal exposure of methylmercury (29 µg/kg-bw/d), Hg(II) (57 
µg/kg-bw/d), Pb(II) (357 µg/kg-bw/d) and reference value ratio (MeHg(I):Hg(II): Pb(II) = 29:87:203) and environmental 
exposure ratio (MeHg(I):Hg(II): Pb(II) = 29:58:493); row B: QT, QRS and QT intervals for one-metal exposure of 
methylmercury (357 µg/kg-bw/d), Hg(II) (357 µg/kg-bw/d), Pb(II) (1607 µg/kg-bw/d) and reference value ratio 
(MeHg(I):Hg(II): Pb(II) = 290:870:2030) and environmental exposure ratio (MeHg(I):Hg(II): Pb(II) = 290:580:4930); 
unpaired student’s t-test *p = 0.01-0.05, **p = 0.001 – 0.01 
4.7 Discussion 
In the current study exposure to mixtures of lead, organic mercury and inorganic mercury 
ameliorated the adverse effects of single metal exposures on some cardiovascular parameters, e.g. 
blood pressure. In contrast, mixtures deteriorated cardiac electrical behaviour while single metal 
exposures had no effect. Although there is increasing evidence in the literature that exposure to 
single metals like Pb(II) or Hg adversely affect the cardiovascular system, no other work so far has 
investigated how metal mixtures influence cardiovascular toxicity. However, some studies with non-
cardiovascular end-points indicate a potential interaction between Pb(II) and Hg species. An in vitro 
study (Fortier et al., 2008) demonstrated that the reduced viability of lymphocytes due to MeHg(I) 
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exposure was mitigated by mixtures containing MeHg(I), CdCl2 and PbCl2. In contrast, in an 
epidemiological study with Inuit children exposed to lead, polychlorinated biphenyls and 
methylmercury (Boucher et al., 2012), developmental effects of Pb exposure were aggravated by Hg 
exposures. Therefore, our study and other mixture studies clearly demonstrate that extrapolating 
adverse effects of metal mixtures cannot be predicted by effects of single metal exposures.  
 
4.7.1 Blood levels 
Blood levels for total Hg and Pb(II) are important biomarkers for recent metal exposure with the 
absorption rate of Hg species depending on their chemical properties (Yokel et al., 2006). While 
absorbed Hg(II) is quickly removed from the blood and accumulates in the kidneys (Bridges and 
Zalups, 2005), MeHg(I) binds to the erythrocytes due to a higher affinity for SH-groups than Hg(II). 
The total Hg blood level is mainly driven by MeHg(I), whereas in our study the blood levels for Pb(II) 
are lower in mixtures than in comparable exposures to only Pb(II). The chemical similarity of Hg(II) 
and Pb(II) might enable them to compete for access to the same metal transporter, e.g. divalent 
metal transporters (Ballatori, 2002), resulting in a reduced absorption of Pb(II). Similarly to Hg, Pb(II) 
has a high affinity to SH-groups (Al-Modhefer et al., 1991), which seems to limit the binding of Pb(II) 
to SH-groups in comparison to MeHg(I).  
 
4.7.2 Blood and pulse pressure 
The result that mixtures reverse the effects on blood and pulse pressure of single metal exposures is 
particularly surprising because total Hg blood levels in the mixture groups are higher than single 
MeHg(I) exposures. While single exposure to MeHg(I) increased blood and pulse pressure, Hg(II) 
and Pb(II) had no effect. However, in a mixture, the Hg(II) and Pb(II) interact with MeHg(I) in an 
antagonistic way so that the overall effect is zero. Our results may explain why epidemiological data 
on the link between mercury and blood pressure are mixed. Epidemiological studies have reported 
positive relationships between Hg hair levels and increased blood pressure in Amazonians (Fillion et 
al., 2006) or between blood Hg levels and systolic blood pressure in Nunavik Inuits (Valera et al., 
2008; 2009), but no relationship between blood or hair Hg levels and hypertension in Cree adults 
(Valera et al., 2011a) or Polynesians (Valera et al., 2011b). Using NHANES data from 2003 – 2006, 
Park et al (2013) found a negative association between urine, but not blood, levels of Hg and blood 
pressure. Similarly, hair Hg levels were positively related to blood pressure, while urine Hg levels 
were inversely related to blood pressure in a study of dental staff (Goodrich et al., 2013b).   
Our data suggests that a simple analysis of total body Pb or Hg levels is not sufficient to unravel the 
link between environmental exposures and adverse cardiovascular effects and underlines the 
importance of the metal species regardless of bioavailability. For example, despite similar blood Hg 
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levels, exposures to MeHg(I) and the mixture with the higher reference value ratio (290:870:2030 
MeHg(I):Hg(II):Pb(II); µg/kg-bw/d) in the current study had dramatically different blood pressure 
outcomes. Because of similar blood Hg levels in our study, the possibility of bioavailability 
differences as explanation is being ruled out. An alternative explanation is that speciation differs 
between the single metal and mixture groups, leading to differences in the adverse outcome 
pathway between MeHg(I) and Hg(II). However, the relationship between different Hg species and 
the exact pathway by which they exert adverse effects is not known. Both Hg species increase 
oxidative stress in the body (Wiggers et al., 2008; Farina et al., 2011) but the target organs might be 
different. Inorganic mercury mainly accumulates in the kidneys (Bridges and Zalups, 2005), which 
play an important role in the long-term regulation of blood pressure via the renin-angiotensin system. 
On the other hand, methylmercury can easily cross the blood-brain barrier and possibly influence the 
blood pressure through the autonomic nervous system (Pappano, 2008). 
4.7.3 Heart function 
While heart rate and stroke volume were not changed, cardiac output was affected by metal 
exposure. As with blood pressure, MeHg(I) and Hg(II) had differing effects on the cardiac output, 
which was decreased by MeHg(I) while Hg(II) and Pb(II) did not have an effect. This is in contrast 
with Skoczynska et al (2014), who observed that the cardiac ejection fraction in Pb(II) exposed rats 
was reduced using magnetic resonance imaging. The discrepancy might be due to the use of two 
different imaging techniques, magnetic resonance imaging versus high-resolution ultrasound. 
Although cardiac output was reduced when the rats were exposed to MeHg(I), combined exposures 
to all three metals did not affect any of these end-points. This indicates an antagonistic interaction 
between MeHg(I), Hg(II) and Pb(II). 
4.7.4 Electrical conductivity 
In contrast to other end-points, mixtures caused increased adverse effects on cardiac electrical 
activity. The different intervals represent different phases of the cardiac cycle. The PR interval 
reflects the activity of the atrioventricular node (Leffler et al., 1994) and was, in our study, mainly 
affected by inorganic mercury exposure. A Hg(II) dose of 57 µg/kg-bw/d produced a prolonged PR 
interval in this study, which completely disappeared in combined exposures with MeHg(I) and Pb(II). 
The QRS interval, which represents the depolarization of the ventricles, was most sensitive to 
combined metal exposure in our study. A prolonged QRS or QT interval is associated with increased 
risk of arrhythmias and sudden cardiac death (Okin et al., 2000). Ratios based on reference values 
show a significant prolongation of the QRS and QT intervals. The main difference between 
regulatory and environmental ratios is the higher amount of Hg(II) in the regulatory ratios. This 
suggests that the electrical activity of the heart might be more susceptible to Hg(II) than to MeHg(I) 
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or Pb(II) exposure. As exposures to only one metal did not show an effect in our study, the combined 
exposure effect indicates synergism. In contrast, to our study, Eum et al (2011) and Cheng et al 
(1998) found prolonged QT and QRS intervals with increasing Pb(II) levels in the tibia and patella by 
analyzing data from the Normative Aging Study. The average age of men in the Normative Aging 
Study was more than 60 years and low level exposure to Pb(II) for decades would have resulted in a 
substantial body burden. On the other hand, the rats in our study were only exposed to Pb(II) for four 
weeks so that the overall body burden is expected to be lower and we did not measure bone Pb 
levels, so we cannot directly compare studies. The discrepancy in the effect of Pb(II) exposure on 
QT and QRS intervals is probably the result of the different exposure durations and as a 
consequence body burdens. 
4.7.5 Population level effects 
HI calculations based on literature values indicate no increased risk for the general population due to 
combined exposures to MeHg(I), Hg(II) and Pb(II). However, the calculation of the HI is based on the 
assumption that the doses are additive and that the metals have a similar modes of action (MOA) 
(U.S. EPA, 2007). Based on our results, it appears that these metals are not additive and that the 
mechanism of action of MeHg(I) may differ from Hg(II). A potential source for increased uncertainty 
of the HI is the fact that the only reference value for a cardiovascular end-point exists for Pb(II), while 
reference values for mercury are based on developmental effects, which mainly affect children.  
Comparing the calculated risk from combined exposures to MeHg(I), Hg(II), and Pb(II) for the 
general population with our study results depends on the selection of cardiovascular end-points. On 
one hand, mixtures showed antagonism for blood and pulse pressure and heart function, which 
would confirm that the public does not have an increased risk for ill-health based on the outcome of 
the risk assessment. On the other hand, combined exposures to MeHg(I), Hg(II) and Pb(II) indicated 
synergistic effects resulting in impaired electrical conductivity in the heart. Hence, for this 
cardiovascular end-point, the outcome of the risk assessment is not protective for human health.  
4.8 Conclusions 
According to our knowledge, this study is the first to investigate combined exposures of MeHg(I), 
Hg(II) and Pb(II) based on the fixed-ratio ray design and examine adverse cardiovascular end-
points. We observed that MeHg(I) and Hg(II) affect the cardiovascular system differently showing the 
importance of the chemical form of the metal. Furthermore, Pb(II) does not affect the cardiovascular 
system in the same way as MeHg(I) or Hg(II). We also found deviation from additivity (synergism 
and antagonism) for the cardiovascular end-points measured. As we observed synergism for 
electrical conductivity, cardiac electrical activity might be the most critical end-point to monitor in 
future studies. An important first step could be to re-analyze data from the major epidemiological 
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studies, such as NHANES and the Normative Aging Study, to investigate the relation between 
hair/urine Hg plus blood Pb(II) levels and the electrical activity of the heart. Results from these 
studies could provide further information on the cardiovascular effects of combined exposures to 
MeHg(I), Hg(II) and Pb(II) specific to humans. 
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5 THE MECHANISMS ASSOCIATED WITH THE DEVELOPMENT OF 
HYPERTENSION AFTER EXPOSURE TO LEAD, MERCURY SPECIES 
OR THEIR MIXTURES DIFFERS WITH THE METAL AND THE MIXTURE 
RATIO 
5.1 Author contributions 
Tanja Wildemann carried out the animal experiment and biochemical analysis of the selected 
tissues. She analyzed the data statistically and prepared the manuscript.  
Steven Siciliano provided scientific input, commented on the manuscript and supported the 
research financially through his research grant. 
Lynn Weber provided scientific input and guidance, edited the manuscript and supported the 
research financially through her research grant.  
5.2 Preface 
To our surprise, the combined exposures reversed most of the adverse cardiovascular effects of 
single metal exposures with the exception of the cardiac electrical activity. By exploring the 
underlying mechanisms of action, namely oxidative stress, kidney damage and DNA methylation, we 
could show that each metal on its own differs in its mechanism of action as well as their mixtures 
supporting the physiological observations.  
Submitted to Toxicology as Wildemann, T.M., Siciliano, S.D., Weber, L.P. (2015) The mechanisms 
associated with the development of hypertension after exposure to lead, mercury species or their 
mixtures differs with the metal and the mixture ratio. 
5.3 Abstract 
Hypertension is considered to be the most important risk factor for the development of 
cardiovascular diseases. Beside life-style risk factors, exposure to lead and mercury species are 
increasingly discussed as potential risk factors. Despite an increasing number of mechanistic 
studies, the underlying mechanism by which exposure to lead and mercury disturb blood pressure 
regulation is not understood. Potential mechanisms are oxidative stress production, kidney damage 
and epigenetic mechanisms, such as DNA methylation, all of which can interact to cause 
dysregulation of blood pressure. Male rats (Wistar) were exposed to lead, inorganic mercury or 
methylmercury or two mixtures of all three metals for four weeks through the drinking water. The two 
mixture ratios were based on known reference values or environmental exposure ratios from the 
literature and levels adjusted to be within the range of single metal doses used. To investigate the 
potential mechanism of actions, blood pressure was measured after four weeks and compared to 
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plasma nitrotyrosine or reduced/oxidized glutathione levels in aorta, heart, kidney and liver as 
markers for oxidative stress. Kidney function was assessed via urinary and plasma creatinine levels 
(also creatinine clearance) and urinary kidney-injury molecule (KIM-1) to assess kidney damage. 
Finally, urinary 5-methyl-2’-deoxycytidine was used as a marker for global DNA methylation. While 
exposure to lead by itself increased oxidative stress and caused kidney damage, methylmercury by 
itself did not affect any of the potential mechanisms investigated. Inorganic mercury was the only 
metal, which showed an increase in global DNA methylation. In contrast, when administered as 
mixtures, lead no longer increased oxidative stress. More interestingly was the observation that 
kidney function, as indicated by creatinine levels, was affected differently between the two different 
metal mixtures. Moreover, only the mixture based on the reference value ratio was associated with 
increased blood pressure. Based on our results, the prominent mechanism of action associated with 
the development of hypertension seems to be oxidative stress and kidney damage for lead and 
reduced kidney function for metal ratios in mixtures.  
 
5.4 Introduction 
Cardiovascular diseases, such as heart attacks and stroke, present a major public health problem 
because these are responsible for the majority of deaths worldwide (Mendis et al., 2011). Although 
hypertension is considered to be the most important risk factor for this group of diseases, its etiology 
is not completely understood (Mendis et al., 2011). In addition to numerous life-style risk factors 
environmental pollutants, such as heavy metals, are gaining more attention as potential risk factors 
contributing to hypertension. The human population is exposed chronically to low levels of lead and 
mercury through the environment (Nawrot et al., 2002; Bautista et al., 2009; Roman et al., 2011; 
Park et al., 2013; Peters et al., 2012). Based on the scientific evidence, lead (Pb(II)) is now 
considered to have a causal relationship with hypertension (Nawrot et al., 2002; Navas-Acien et al., 
2007; Glenn et al., 2003). The relationship between mercury exposure and hypertension is less 
clear. A positive association between mercury exposure and hypertension was found in some 
human studies (Bautista et al., 2009; Valera et al., 2009; Pedersen et al., 2005), while a negative 
association was found in another set of epidemiological studies (Vupputuri et al., 2005; Johansson et 
al., 2002; Mozaffarian et al., 2011; 2012; Valera et al., 2011a; Park et al., 2013).  
Despite an increasing number of mechanistic studies, the underlying mechanism(s) by which 
exposures to Pb(II), inorganic mercury (Hg(II)), organic mercury (MeHg(I)) or their mixtures influence 
blood pressure is not understood. One leading hypothesis for mechanism of action of metals is 
oxidative stress. Exposure to either Pb(II) or Hg has been reported to cause increased production of 
reactive oxygen species (ROS) (Ercal et al., 2001), depletion of antioxidant defenses or both 
(Saeidnia and Abdollahi, 2013). In addition, studies have shown that Pb(II) exposure increased the 
 64 
production of ROS, such as superoxide and this secondarily decreased the availability of nitric oxide 
(NO) leading to the production of the highly toxic peroxynitrite (Farmand et al., 2005;Ding et al., 
2001;Vaziri et al., 2003;Vaziri, 2008). At the same time, Pb(II) exposure reduces the available 
amount of antioxidant glutathione (Kasperczyk et al., 2004). Similarly, Hg(II) and MeHg(I) have also 
been reported to decrease the availability of NO through increased ROS production (Wiggers et al., 
2008; de Marco et al., 2009; Lemos et al., 2012). In particular MeHg(I) has a high affinity for the 
sulfhydryl groups of glutathione, resulting in inactivated glutathione and depleted antioxidant 
defenses (Ballatori, 2002). The well-known consequences of disturbances in ROS production, 
depleted antioxidants and NO inactivation are numerous, but include endothelial dysfunction, 
vasoconstriction and hypertension (Li and Foerstermann, 2000).  
In addition to the central nervous system, the kidneys play a crucial role in blood pressure regulation 
(Wadei and Textor, 2012). Therefore, impaired kidney function due to exposure to Pb(II) and Hg is a 
second mechanism that may be important for the development of hypertension. Analyzing data from 
the Third National Health and Nutrition Examination Survey (NHANES) (Muntner et al., 2003) and 
the Normative Aging Study (Tsaih et al., 2004) showed positive associations between Pb body 
burdens and increased serum creatinine concentrations, a biomarker for impaired kidney function 
(Vlasakova et al., 2014). The kidneys are the target organ for the accumulation of Hg(II), making 
Hg(II) particularly nephrotoxic (Zalups, 2000). The proximal tubule of the nephron (Zalups, 2000; 
Massanyi et al., 2007) is the main target of Hg(II), resulting in increased serum creatinine levels (Shi 
et al., 2011).  
Epigenetic mechanisms and in particular DNA methylation, which mainly occurs at the so called 
CpG-islands, are also increasingly recognized as playing an important role in the development of 
human diseases, including cardiovascular disease (Robertson, 2005; Shirodkar and Marsden, 
2011). As Pb(II) and Hg are generally classified as neurotoxicants, the few studies available 
investigating the influence of DNA methylation focused on neurotoxicity, not cardiovascular effects, 
but similar mechanisms are likely to affect both systems. The major conclusion to be drawn from 
these initial studies are that Pb(II) and Hg (Hanna et al., 2012) both alter the methylation status of 
genes and thus influence important biochemical pathways. DNA hypermethylation due to Pb(II) 
exposure was observed in animal and human studies (Kovatsi et al., 2010; Schneider et al., 2013). 
Although mercury species showed increased DNA methylation in animals (Onishchenko et al., 2008; 
Pilsner et al., 2010), Hg(II) and MeHg(I) seem to affect DNA methylation differently (Goodrich et al., 
2013a) in humans. While MeHg(I) indicated a trend to reduce DNA methylation of SEPP1, Hg(II) did 
not show an effect (Goodrich et al., 2013a). Despite the existence of studies indicating a link 
between Pb(II) and mercury exposure and adverse cardiovascular effects through changes in DNA 
methylation, little is known about the detailed mechanism. 
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Based on a previous study in our lab (Wildemann et al., 2015), we showed that exposures to Pb(II) 
or MeHg(I), but not Hg(II), each as single metals alone increased the blood pressure in rats. In 
contrast, in a follow-up study (Wildemann et al., 2014), we found that mixtures of these three metals 
had no effect on blood pressure. These results were puzzling since these initial studies showed that 
metal blood levels were similar or perhaps even higher after mixture exposures compared to the 
metals alone (Wildemann et al., 2014), indicating that altered bioaccumulation was not the 
mechanism responsible for loss of blood pressure effect of metal mixtures. Therefore, we 
hypothesized that oral exposure to Pb(II), Hg(II), MeHg(I) had different mechanisms of action 
compared to exposure to their mixtures; specifically, we hypothesized that blood pressure alterations 
after four weeks of exposure in rats occurred through three different mechanisms, namely oxidative 
stress, kidney function and damage and/or changes in DNA methylation. In order to investigate this 
hypothesis, we assessed oxidative stress by measuring plasma nitrotyrosine and oxidized/reduced 
glutathione in aorta, kidney, heart and liver. Metals, such as Pb(II) and Hg species, are well known to 
increase oxidative stress. Since peroxynitrite is formed when both nitric oxide (NO) and superoxide 
(O2
-
) are present in high levels, this can be used as a measure of oxidative stress. Peroxynitrite has 
a high affinity for covalently modifying many different macromolecules, but has a high affinity for 
tyrosine residues in proteins, thereby forming nitrotyrosine. 
Thus, nitrotyrosine is a surrogate that can be used to indicate both oxidative stress and inactivation 
of the biological effect of nitric oxide in the cardiovascular system. Kidney function was evaluated 
with urinary and plasma creatinine, allowing creatinine clearance to be calculated, and kidney 
damage evaluated with urinary Kidney Injury Molecule 1 (KIM-1; biomarker for proximal tubule 
injury) (Vlasakova et al., 2014). Creatinine is freely filtrated, but not reabsorbed, by the kidneys and 
is therefore a good marker for glomerular filtration and kidney function. While plasma creatinine can 
be influenced by protein metabolism, the clearance of creatinine should remain constant in a healthy 
animal. While creatinine levels and clearance have known ranges for clinical norms, KIM-1 protein is 
a biomarker for proximal tubule injury in the kidney and is normally low in a healthy individual. Global 
changes in DNA methylation were measured using urinary 5-methyl-2’-deoxycytidine (Itoh et al., 
1995). Methylation of DNA is a mechanism to regulate the expression of a gene, with 
hypermethylation of the promoter region for a given gene resulting in reduced gene expression. 
Global hyper- or hypomethylation is associated with diseases such as cancer, atherosclerosis and 
rheumatoid arthritis, but the effects of heavy metals on this epigenetic mechanism in cardiovascular 
toxicity are not fully understood (Ray et al., 2014). DNA methylation status can be represented as 
the amount of free 5-methyl-2’-deoxycytidine in urine. Methylation remains intact on deoxycytidine 
during normal turnover/repair of DNA and thus urinary levels are most closely linked to the global 
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level of methylation in the body. The patterns of change in these metal mechanisms of action were 
then compared to alterations in blood pressure after four weeks of exposure in male rats. 
 
5.5 Materials and methods 
5.5.1 Animals and exposures 
Male rats (Wistar strain, 250-300 g) were obtained from Charles River Laboratories, Senneville, QC, 
Canada and were housed in single cages, at 22°C room temperature and a 12:12H-light dark cycle 
at the Western College of Veterinary Medicine at the University of Saskatchewan (Saskatoon, SK, 
Canada). The animals were acclimatized for one week and had access to standard rat chow ad 
libitum. For the duration of four weeks, rats (n = 5-6/group) received either lead acetate (Pb(II)), 
mercury chloride (Hg(II)), mono-methylmercury chloride (MeHg(I)) or a mixture of all three metals 
through the drinking water (tap water with 0.2% nitric acid). Rats exposed to Pb(II) received either 
1607 or 45000 µg Pb(II)/kg-bw/d, to Hg(II) either 357 or 4000 µg Hg(II)/kg-bw/d and to MeHg(I) 
either 7 or 357 µg MeHg(I)/kg-bw/d via the drinking water. Mixture ratios were based on published 
reference values or on published environmental exposure values (EFSA, 2012b; 2012a). For the 
reference values based ratio (R), the ratio was MeHg(I):Hg(II):Pb(II) = 1:3:7. In a previous study 
(Wildemann et al., 2015), a MeHg(I) dose of 290 µg/kg-bw/d showed significant adverse effects on 
blood pressure. As MeHg(I) is the most toxic of these three metals, this dose was used as starting 
dose, resulting in a ratio of MeHg(I):Hg(II):Pb(II) = 290:870:2030 µg/kg-bw/d. Similarly, the 
environmental exposure ratio (E) was established. The published values for environmental exposure 
resulted in a ratio of MeHg(I):Hg(II):Pb(II) = 1:2:17. Using 290 µg MeHg(I)/kg-bw/d as the starting 
dose leads to a ratio of MeHg(I):Hg(II):Pb(II) = 290:580:4930 µg/kg-bw/d (Table 5.1).  
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Table 5.1. Ratios for combined exposures. 
 
 MeHg(I) 
(µg/kg-bw/d) 
Hg(II) 
(µg/kg-bw/d) 
Pb(II) 
(µg/kg-bw/d) 
Reference values 
Ratio  
0.23 
1 
0.57 
3 
1.5 
7 
Environmental exposure values 
Ratio  
0.039 
1 
0.08 
2 
0.68 
17 
Experimental ratios    
Reference values (R) 290 870 2030 
Environmental exposure values (E) 290 580 4930 
 
Reference values and environmental exposure values were obtained from the published literature and used to define 
MeHg(I):Hg(II):Pb(II) ratios for mixtures. MeHg(I) is the most toxic of these metals and was hence used as the 
starting point. In a previous study, a MeHg(I) dose of 290 µg/kg-bw/d showed an increase in blood pressure 
(Wildemann et al., 2015).  
 
The drinking water of the control rats (n = 6/group) consisted of tap water with 0.2% nitric acid. At the 
end of the exposure duration, the animals were euthanized. Blood, urine and tissues were collected, 
processed as appropriate and stored at -80°C until further analysis. 
Chemicals were obtained from Sigma-Aldrich (Oakville, ON, Canada).The Animal Research Ethics 
Board at the University of Saskatchewan approved all procedures in this experiment and were 
carried out according to the guidelines of the Canadian Council on Animal Care (CCAC). 
5.5.2 Blood pressure measurement 
For blood pressure measurements after four weeks of exposure, rats were anesthetized (induction 
with 5% isoflurane and 1-3% for maintenance), injected with 3 ml saline (s.c.) and placed on a 
heating blanket (37°C). The systolic and diastolic blood pressure was measured by inserting a pre-
calibrated (calibrated to a mercury column), saline-filled pressure catheter into the femoral artery. 
Values were recorded for 10 minutes using a PowerLab (ADInstruments, Colorado Springs, CO, 
USA). Average values from each rat were used for statistical analysis. Rats were then euthanized 
immediately after blood pressure and ECG recording followed by collection of blood and tissues. 
5.5.3 Oxidative stress 
Nitrotyrosine levels (an indicator of peroxynitrite formation) were measured in plasma samples (n = 
5-6/group) with a commercially available ELISA based enzyme-linked immunosorbent assay 
(Nitrotyrosine ELISA Kit, Hycult biotech, The Netherlands). After collection, aorta, heart, kidney and 
liver tissues were homogenized, deproteinated and stored at -80°C until further processing. Samples 
were analyzed for their oxidized (GSSG) and the total GSH (which were then used to calculate 
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GSSG/GSH ratio) using a commercially available enzymatic assay (Glutathione Assay Kit, Cayman 
Chemical Company, Ann Arbor, MI, USA). Based on the measured amounts of GSSG and total 
GSH, the ratio GSSH/total GSH was calculated. 
5.5.4 Kidney function and damage 
Creatinine levels were analyzed in urine and plasma samples (n = 5-6/group) using an assay based 
on a coupled enzyme reaction (Creatinine Assay Kit, Sigma-Aldrich, St. Louis, MO, USA) as 
indicators of kidney function. Based on the plasma and urine concentrations, the creatinine 
clearance (CCR in µl/min) was calculated as the product of creatinine concentration in urine (UCR in 
ng/µl) and urine flow (V in µl/min) divided by the creatinine plasma concentration (PCR in ng/µl). Urine 
flow was not measured directly and was assumed to be 15 µl/min for all rats, based on published 
values (Wuthrich, 2000). Kidney Injury Molecule-1 (KIM-1) is a biomarker for injury to the proximal 
tubule of the kidney. Its concentration was measured in urine samples (n = 5-6/group) with a 
commercially available in vitro ELISA Immunosorbent Assay (KIM-1 Rat ELISA Kit, Abcam, 
Cambridge, England). 
5.5.5 DNA methylation 
The global DNA methylation status was measured in urine (n = 5-6/group) using a commercially 
available competitive enzyme immunoassay (DNA Methylation EIA Kit, Cayman Chemical Company, 
Ann Arbor, MI, USA). 
5.5.6 Statistical analysis 
The animals were either exposed to one metal (MeHg(I), Hg(II), Pb(II)) or a mixture of all three 
metals. Grubb’s test was used to detect outliers. Values with a p < 0.05 were considered to be 
significantly different and removed. Results are presented as mean ± standard deviation (SD). Data 
were evaluated for normality and homogeneity of variance with Komogorov-Smirnow and Bartlett’s 
tests. The data satisfied the requirements for parametric statistics. Differences were analyzed by 
one-way Analysis of Variance (ANOVA) followed by Fisher’s Least Significant Difference (LSD) post-
hoc test (GraphPadPrism, GraphPad Software, Inc., San Diego, CA, USA). A p < 0.05 was 
considered significant.  
 
5.6 Results 
5.6.1 Blood pressure  
Among the numerous risk factors for cardiovascular diseases, hypertension is considered to be the 
most important. In the current study, blood pressure (Figure 5.1) was increased by single exposures 
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to Pb(II), Hg (II), MeHg(I) and the mixture based on the reference value ratio (R = 
MeHg(I):Hg(II):Pb(II) = 290:870:2030), but not by the mixture based on the environmental exposure 
ratio (E = MeHg(I):Hg(II):Pb(II) = 290:580:4930). The Pb(II) doses (1607 and 45000 µg/kg-bw/d) 
showed a significant increase of 20 mmHg in systolic blood pressure compared to the control group 
(Figure 5.1), an increase sufficiently large to make a normotensive individual hypertensive. Similarly, 
exposure to MeHg(I) raised the systolic blood pressure by 15 mmHg for the lower dose (7 µg 
MeHg(I)/kg-bw/d) and 27 mmHg for the higher MeHg(I) dose (357 µg/kg-bw/d) in comparison to the 
control group. In contrast, Hg(II) did not significantly affect systolic blood pressure at any dose. 
Differences were observed between the two mixtures. While the systolic blood pressure was also 
increased for the reference values ratio (R) compared to the controls, no change was observed for 
the environmental exposure ratio (E). Comparing single metal exposures to both mixtures, the 
systolic blood pressure was increased by the mixture based on the reference values ratio compared 
to the higher Hg(II) dose (4000 µg/kg-bw/d). The systolic blood pressure was decreased by the 
environmental exposure ratio in comparison to the higher MeHg(I) dose (357 µg/kg-bw/d) and the 
mixture based on the reference value ratio.  
 
Fig. 5.1. Systolic and diastolic blood pressure in rats (n=5-6 rats/group) after 4 weeks of exposure to lead, inorganic 
mercury or methylmercury or a mixture of all three metals through the drinking water. Data are shown as mean ± 
standard error of mean. Horizontal line shows the mean value for the control group (dotted line). Single exposures 
were compared to control and mixtures in Fisher’s LSD posteriori test after one-way ANOVA. * indicates significance 
versus control group, # significance versus R, $ significance versus E. A p< 0.05 was considered to be significant. 
Changes in diastolic blood pressure after metal exposure showed a similar pattern of effect as 
systolic pressure changes (Figure 5.1). For both Pb(II) doses, diastolic pressure was increased 
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compared to the control group. The lower Hg(II) dose significantly raised the diastolic blood pressure 
by 11 mmHg in comparison to controls, while the higher Hg(II) dose was not different from the 
control group. Similarly, the lower MeHg(I) dose was not different from the control group, but the 
higher MeHg(I) dose raised the diastolic blood pressure by 20 mmHg. For the mixtures, the pattern 
for diastolic blood pressure was the same as for systolic blood pressure. The reference values ratio 
(R) increased the diastolic blood pressure, while the environmental exposure ratio (E) was not 
different from the control group. As seen with systolic blood pressure, the diastolic blood pressure 
was decreased for 4000 µg Hg(II)/kg-bw/d in comparison to the mixture based on the regulatory 
value ratio. The diastolic blood pressure for the mixture based on the environmental exposure ratio 
was reduced compared to both Pb(II) doses (1607 and 45000 µg/kg-bw/d) and the higher MeHg(I) 
dose (357 µg/kg-bw/d). 
5.6.2 Oxidative stress 
The Pb(II) dose of 45000 µg/kg-bw/d significantly increased the nitrotyrosine plasma levels by about 
350% in comparison to the control group and the two mixtures (Figure 5.2). In contrast, both Hg(II) 
and both MeHg(I) doses and the two mixtures were not different from the control group. This 
indicates that Pb(II) has an exposure threshold for the production of oxidative stress and inactivation 
of nitric oxide, while Hg species and mixtures do not seem to affect this pathway.  
 
 
Fig. 5.2. Plasma nitrotyrosine in rats (n=3-6 rats/group) after 4 weeks of exposure to lead, inorganic mercury or 
methylmercury or a mixture of all three metals through the drinking water. Data are shown as mean ± standard 
deviation. Horizontal line shows the mean value for the control group (dotted line). Single exposures were compared 
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to control and mixtures in Fisher’s LSD posteriori test after one-way ANOVA. * indicates significance versus control 
group, # significance versus R, $ significance versus E. A p< 0.05 was considered to be significant. 
Glutathione is an intracellular antioxidant system that counteracts oxidative stress. In liver tissue, 
none of the single or combined exposures increased significantly total GSH compared to control 
(Figure 5.3A). Significant changes were observed for GSSG for both Pb(II) doses compared to the 
two mixtures but not to the control group (Figure 5.3B). The ratio of GSSG to total GSH (Figure 
5.3C) was significantly increased for the higher Pb(II) dose of 45000 µg/kg-bw/d and the lower Hg(II) 
dose of 357 µg/kg-bw/d compared to the control group and both mixtures.   
 
 
Fig. 5.3. Total GSH, GSSG and their ratio in liver tissue in rats (n=4-6 rats/group) after 4 weeks of exposure to lead, 
inorganic mercury or methylmercury or a mixture of all three metals through the drinking water. Data are shown as 
mean ± SD. Horizontal line shows the mean value for the control group (dotted line). Single exposures were 
compared to control and mixtures in Fisher’s LSD posteriori test after one-way ANOVA. * indicates significance 
versus control group, # significance versus R, $ significance versus E. A p< 0.05 was considered to be significant. 
No significant changes for total GSH, GSSG or their ratio was observed in aorta, heart or kidney 
(data not shown). 
5.6.3 Kidney function and damage 
Plasma creatinine levels were not affected by any of the single or combined exposures in 
comparison to the control group or to the mixtures (Figure 5.4A). In contrast to the plasma creatinine 
levels, urine creatinine levels were significantly elevated compared to control (Figure 5.4B) by about 
200% for the lower Hg(II) dose and the higher dose of MeHg(I) and by about 280% for the 
environmental exposure ratio (E). Moreover, the environmental exposure ratio (E) was further 
increased in comparison to both Pb(II) doses, the higher Hg(II) dose, the lower MeHg(I) dose and  
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210% for the reference values ratio (R), highlighting differences in response to different metal 
mixtures. For the creatinine clearance, only the lower Pb(II) dose showed a significant increase 
compared to the control group and the mixtures (Figure 5.4C). 
 
Fig. 5.4. Creatinine levels in plasma (A), in urine (B) and creatinine clearance (C) in rats (n=4-6 rats/group) after 4 
weeks of exposure to lead, inorganic mercury or methylmercury or a mixture of all three metals through the drinking 
water. Data are shown as mean ± SD. Horizontal line shows the mean value for the control group (dotted line). Single 
exposures were compared to control and mixtures in Fisher’s LSD posteriori test after one-way ANOVA. * indicates 
significance versus control group, # significance versus R, $ significance versus E. A p< 0.05 was considered to be 
significant. 
The amount of KIM-1 in urine was significantly increased for the lower Pb(II) dose in comparison to 
the control group (Figure 5.5). No other significant differences among treatments were observed for 
urinary KIM-1. 
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Fig. 5.5. KIM-1 levels in urine in rats (n=3-6 rats/group) after 4 weeks of exposure to lead, inorganic mercury or 
methylmercury or a mixture of all three metals through the drinking water. Data are shown as mean ± SD. Horizontal 
line shows the mean value for the control group (dotted line). Single exposures were compared to control and 
mixtures in Fisher’s LSD posteriori test after one-way ANOVA. * indicates significance versus control group, # 
significance versus R, $ significance versus E. A p< 0.05 was considered to be significant. 
5.6.4 DNA methylation 
In our study, free urinary 5-methyl-2’-deoxycytidine (Figure 5.6) was significantly increased for both 
Hg(II) doses but not for any of the other exposures. 
 
 
Fig. 5.6. Concentration of 5-methyl-2’-deoxycytidine was measured after four weeks of exposure in urine. Rats (n=5-
6 rats/group) received either one metal Pb(II), Hg(II) or MeHg(I) or a mixture based on reference values (R) or 
environmental exposures (E) through the drinking water. Data are shown as mean ± SD. Horizontal line shows the 
mean value for the control group (dotted line). Single exposures were compared to control and mixtures in Fisher’s 
LSD posteriori test after one-way ANOVA. * indicates significance versus control group, # significance versus R, $ 
significance versus E. A p< 0.05 was considered to be significant. 
5.7 Discussion 
In contrast to single metal exposure to Pb(II) and the lower Hg(II) dose, exposure to mixtures of all 
three metals did not affect oxidative stress production, indicating antagonism. While effects of metal 
mixtures on oxidative stress and kidney function were consistent with each other, mixture effects 
diverged for blood pressure depending on the mixture ratio. Although no comparable study with the 
same metal combination used in the current study is available, single and co-exposure to lead, 
cadmium and arsenic (Fowler et al., 2004) showed similar results on oxidative stress production 
depending on single metal exposure or combined exposures. Therefore, all three metals seem to 
affect the cardiovascular system through different mechanisms.  
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Pb(II) supports the development of hypertension through kidney injury and disturbing the 
ROS/antioxidant system, while MeHg(I) might act through a decrease of kidney function. Global 
DNA methylation was significantly altered by Hg(II), which did not elevate blood pressure, indicating 
that this mechanism of action is not associated with the development of hypertension.  
5.7.1 Oxidative stress 
Our data show that Pb(II) may cause hypertension through a combination of increasing oxidative 
stress production and kidney damage. Increased plasma nitrotyrosine levels are the result of an 
increased production of O2
-
, a sign for oxidative stress, as well as inactivation of nitric oxide, effects 
generally accepted to increase blood pressure (Vaziri and Khan, 2007). In agreement with our study, 
Ding et al (2001) showed an increase in nitrotyrosine in rats exposed to low levels of Pb(II) (100 
ppm). The GSH/GSSG system is an internal antioxidant system and an increased GSSG level a sign 
for oxidative stress.  
While none of the metal treatments increased GSSG levels in liver compared to the control group, 
any GSSG produced as a result of oxidative stress would be recovered to GSH via actions of the 
enzyme glutathione peroxidase (Bhabak and Mugesh, 2010). Previous studies have reported that 
levels of this enzyme were not altered after Pb(II) exposure (100 ppm) in rat aorta (Farmand et al., 
2005) or in kidney, brain and left ventricle (100 ppm) (Vaziri et al., 2003), agreeing with results with 
GSSG in this study. In contrast, a human study of lead exposure in an occupational setting 
(Kasperczyk et al., 2004) showed an increase in glutathione peroxidase in erythrocytes (blood Pb 
level: 25-40 µg/dL). A reason for the discrepancy is likely due to differences between liver tissue and 
erythrocytes and the potentially longer exposure duration in humans than in experimental rats.  
Mercury is another representative of a metal with the reported ability to induce oxidative stress. 
Previous studies reported that in aorta from rats (Wiggers et al., 2008; Lemos et al., 2012) and 
humans (de Marco et al., 2009) there was a decrease in NO availability. Also, MeHg(I) is reported to 
bind to GSH and inactivate this complex (Bridges et al., 2012). However, in the current study, 
MeHg(I) did not affect the GSH/GSSG system. Therefore, mechanisms other than those examined 
are likely linked to the ability of MeHg(II) to increase blood pressure such as alterations in autonomic 
neural function or renin-angiotensin system activation. Moreover, inorganic mercury did not seem to 
act through oxidative stress production with only disturbing the GSSG/GSH ratio at the lower Hg(II) 
dose. Taken together, we observed that Pb(II), but not MeHg(I) or Hg(II), disturbs the delicate 
balance between ROS and antioxidants which may be a mechanism for the development of 
hypertension.  
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5.7.2 Kidney function and damage 
Our study found that none of the metals decreased plasma creatinine levels. In contrast, data from 
the Normative Aging Study (Kim et al., 1996) showed a significant relation between low level lead 
and increased serum creatinine, which is corroborated by findings from NHANES (Muntner et al., 
2003; Fadrowski et al., 2010). This discrepancy might be due either to differences in exposure 
duration or species differences. A Canadian research group (Dutton et al., 2013; Zwicker et al., 
2014) showed a positive association between urinary mercury from dental amalgam and urinary 
creatinine. We found links between urinary creatinine and the lower Hg(II) dose and the higher  
MeHg(I) dose. While not showing a consistent dose-related pattern, others have found that exposure 
for 60 days to Hg(II) or MeHg(I) increased serum creatinine for MeHg(I), but not for Hg(II) (Shi et al., 
2011). We observed that urinary creatinine levels differed depending on the metal ratio in a mixture 
with normal levels for the mixture based on the reference value ratio and an increase for the mixture 
based on the environmental value ratio.  
An opposite pattern was observed with urinary KIM-1. Albeit not significant the mixture based on the 
reference value ratio appeared to increase urinary KIM-1, while the mixture based on environmental 
value ratio was comparable to the control group values. This suggests that the proximal tubule could 
be a target depending on the metal ratio. As the mixtures reversed the effect of Pb(II) exposure 
alone, Hg species seem to antagonize the potential kidney injury through Pb(II). In summary, kidney 
damage due to Pb(II) exposure has the potential to be linked to changes in blood pressure, while 
MeHg(I) does not seem to inflict injury of the proximal tubule. 
5.7.3 DNA methylation 
In our study, exposure to Pb(II) and MeHg(I) did not alter global DNA methylation in urine but 
increased blood pressure. In contrast, Hg(II) did not increase blood pressure but significantly 
changed urinary global DNA methylation, indicating that global DNA methylation is not associated 
with blood pressure regulation. As only global DNA methylation was analyzed, it is impossible to 
relate the results to specific genes relevant for the homeostasis of the cardiovascular system in our 
animal experiment. Other studies using cell lines, have found that alterations in DNA methylation of 
genes involved in cardiovascular health are potentially associated with the development of 
cardiovascular diseases. In cells, Chan et al (2004) showed that DNA methylation is a key 
mechanism to steer the expression of the eNOS gene which is involved in NO metabolism. Kim et al 
(2010) go a step further and suggest DNA methylation as a biomarker to assess cardiovascular risk 
in humans based on their finding that increased DNA methylation in peripheral blood leukocytes has 
a direct association with the prevalence of cardiovascular diseases. Future studies examining 
epigenetic mechanisms with metals and a possible link to hypertension should examine methylation 
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of specific genes of interest to this system or possibly use leukocytes instead of urinary 
deoxynucleotides as marker. 
5.8 Conclusions 
Based on our knowledge, this is the first time that exposures to MeHg(I), Hg(II) or Pb(II) and their 
mixtures were compared regarding their ability for oxidative stress production, kidney 
function/damage and DNA methylation as potential mechanisms of action for the development of 
hypertension. We observed that each of the three metals had different effects on the three potential 
mechanisms of action. Pb(II) could be linked to blood pressure increase through oxidative stress and 
kidney damage. Although MeHg(I) increased blood pressure, it did not alter oxidative stress levels or 
impair kidney function. Neither of these two metals altered global DNA methylation in contrast to 
Hg(II), which showed no increased oxidative stress or adverse effect on the kidneys, which is in 
agreement with the only minor effect on blood pressure. Therefore, global DNA methylation appears 
not to be associated with the development of hypertension. Moreover, effects of mixture ratios 
differed but generally diminished blood pressure effects of single metals. However, effects on 
plasma and urinary creatinine levels indicate opposite effects on the kidney function between the two 
mixtures. Our results show lead and mercury species may act through different mechanisms of 
actions on blood pressure, but the mechanism of action is still unclear for all metals examined, 
particularly for methylmercury. Moreover, exposing rats to different mixtures produced different 
effects on both blood pressure and potential mechanisms, highlighting the difficulty in extrapolating 
single metal animal studies to human populations where exposures are generally to complex 
mixtures. 
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6 SYNTHESIS AND CONCLUSIONS 
Cardiovascular diseases, such as heart attacks and stroke, are the major cause of death worldwide 
(Laslett et al., 2012). In addition to life-style and metabolic risk factors, environmental pollutants are 
increasingly discussed (Mendis et al., 2011). Lead and mercury species are ubiquitously present in 
the environment leading to chronic, low dose exposure in humans. While Pb(II) is clearly related to 
hypertension, additional cardiovascular end-points are poorly studied. Even less evidence exists for 
a relation between exposure to mercury species and adverse cardiovascular effects. Hence, the 
contribution of these metals to the prevalence of CVDs is not known.  
The main goals of the presented research were to 
1. Identify cardiovascular effects of single exposures to Pb(II), Hg(II) and MeHg(I),  
2. Explore cardiovascular effects of combined exposures to Pb(II), Hg(II) and MeHg(I),  
3. Investigate underlying mechanisms of action, e.g. oxidative stress, kidney damage and DNA 
methylation, for cardiovascular effects.  
The research results provided answers to questions, such as: Are Pb(II), Hg(II) and MeHg(I) risk 
factors for the development of CVDs? Which is the most sensitive cardiovascular end-point? Do safe 
exposure thresholds exist? Do mixture effects deviate from additivity? Do these metals elicit 
cardiovascular toxicity through the same mechanisms?  
6.1 Main findings 
Blood pressure was affected by Pb(II) and MeHg(I) but not by Hg(II) exposure. Pb(II) showed a 
biphasic dose-response curve with a blood pressure decrease at doses ≤ 29 µg/kg-bw/d and 
increased blood pressure at doses ≥ 1607 µg/kg-bw/d (Figure 3.1). A dose of 357 µg Pb(II)/kg-bw/d 
yielded a BLL of 17 ± 7 µg/L (Table 3.2), which corresponds to a BLL in the general population. 
Considering a linear relation between Pb(II) exposure and BLL, it can be assumed that doses at 
which a decrease in blood pressure was observed are too low to be relevant for human exposure. 
However, increased blood pressure was observed at BLLs (Table 3.2), which can be found in the 
general population and in occupational settings. Hence, Pb(II) exposure in the human population can 
be considered as a risk factor for hypertension. The mercury species MeHg(I) and Hg(II) differ in 
their effects on blood pressure. While MeHg(I) increased blood pressure at even low doses (≥ 7 
µg/kg-bw/d) (Figure 3.1), Hg(II) did not affect blood pressure but had a mortality rate of 100% at a 
dose of 4000 µg Hg(II)/kg-bw/d (Table 3.1). As a consequence, it will be important to specify the 
mercury species at exposure level. Furthermore, these findings might explain the inconclusive 
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results on mercury exposure and blood pressure from epidemiological studies which often do not 
differentiate between exposure to MeHg(I) and Hg(II).  
The human population is generally exposed to mixtures of chemicals. In the case of Pb(II) and 
mercury, Pb(II) exposure occurs through food and drinking water (Health Canada, 2013), mercury 
vapor from dental amalgam fillings (Richardson and Allan, 1996), which is quickly oxidized to Hg(II) 
in the body and MeHg(I) through fish and seafood (EFSA, 2012a). In mixture toxicology, it is 
assumed that the mixture components do not interact, i.e. they are additive (U.S. EPA, 1986). For 
the mixture experiment, it was also assumed that exposure to MeHg(I), Hg(II) and Pb(II) occur based 
on fixed ratios. Therefore, literature values for published reference and environmental exposure 
values were used as base for combined exposures (Table 4.1). The results from the mixture 
experiment showed that the assumption of additivity is wrong. The adverse effects on blood 
pressure from exposures to Pb(II) and MeHg(I) alone were reversed and normal blood pressure 
levels observed (Figure 4.1) indicating antagonism. In contrast, combined exposures to Pb(II), Hg(II) 
and MeHg(I) adversely affected the cardiac electrical activity (synergism), which was not affected by 
single exposures (Figure 4.3). Therefore, it is not possible to predict the cardiovascular effects from 
combined exposures from single exposures to MeHg(I), Hg(II) and Pb(II). In addition to the 
cardiovascular system, the blood levels of Pb(II) and total mercury differed between single metal and 
combined metal exposure. While the BLL decreased compared to single Pb(II) exposure, the total 
mercury blood level was increased (Table 4.3). As the blood pressure was not increased with 
combined exposure, the blood levels of the metals are not a reliable marker for changes in blood 
pressure. Furthermore, differences based on the mixture ratios were observed. Exposures based on 
the reference values ratio increased BLL and total mercury blood levels more than the environmental 
exposure ratio (Table 4.3). A similar pattern was visible with cardiovascular end-points, such as 
blood pressure (Figure 4.1), heart rate (Figure 4.2) and electrical activity of the heart (figure 4.3), 
which indicates the importance of the metal ratio.  
Epidemiological studies show a clear association between Pb(II) and blood pressure (Scinicariello et 
al., 2011; Cheng et al., 2001; Nash et al., 2003), while the same relation for mercury is unclear 
(Bautista et al., 2009; Mozaffarian et al., 2012). This type of studies usually focus on Pb(II) exposure 
or mercury exposure and therefore, neglecting potential mixture effects. The presented findings 
show that neither blood levels nor effects from single exposure are reliable predictors for effects from 
combined exposures, which is the reality in the human population. Thus, epidemiological studies 
need to be analyzed for combined exposures to Pb(II) and mercury species and the metal ratio be 
calculated.  
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The differences between the cardiovascular effects of single metal and combined exposure were 
surprising and could not be explained by the blood levels of Pb(II) and total mercury. As 
hypertension is the major risk factor for the development of CVDs, effects at cellular and molecular 
level were investigated to elucidate the mechanisms for blood pressure development. Blood 
pressure increase was observed with single exposures to Pb(II) or MeHg(I) and to the reference 
value ratio, but not for Hg(II) or the environmental exposure ratio (Figure 5.1). Metals, such as Pb(II) 
and mercury species are well known to increase oxidative stress (Ercal et al., 2001). While single 
exposure to Pb(II) raised the production of oxidative stress (Figures 5.2 and 5.3), no changes were 
observed with mercury. This indicates that oxidative stress is a mechanisms for blood pressure 
increase due to single metal exposure to Pb(II). Although exposure to the reference value ratio 
increased blood pressure, no change in oxidative stress production was observed indicating that 
metal mixtures act through a different mechanism than single metal exposure. Pb(II) and mercury 
are known systemic toxicants and have the ability to adversely affect e.g. the kidneys, which play an 
important role in blood pressure regulation. The kidney function might be affected by single exposure 
to mercury but the dose-response relation is not clear (Figure 5.4). As seen with cardiovascular end-
points, the effects of the mixtures differed depending on the ratio. While only the mixture based on 
the environmental exposure ratio showed an adverse effect on the kidney function (Figure 5.4), the 
blood pressure increase was observed with the mixture based on the reference value ratio (Figure 
5.1). With regard to kidney damage, only Pb(II) exposure showed an adverse effect (Figure 5.5) 
indicating a second mechanism for the development of hypertension (Figure 5.1). The mixtures 
differed again with respect to their effect on kidney damage but in the opposite way. While the 
mixture based on the reference value ratio showed a trend to negatively affect the kidney, the 
mixtures based on the environmental exposure ratio had no effect (Figure 5.5). A third potential 
mechanism for the alteration of blood pressure due to metal exposure is the change of the global 
DNA methylation. While Pb(II), MeHg(I) and the mixtures did not show an effect, Hg(II) raised the 
global DNA methylation (Figure 5.6). However, Hg(II) was the metal which did not affect blood 
pressure. Thus, it can be assumed that global DNA methylation might not be a mechanism for the 
development of hypertension.  
6.2 Strengths and limitations 
A broad range of cardiovascular effects were evaluated with high-resolution ultrasound and a 
catheter inserted into the femoral artery. Due to the high sensitivity of these methods, it was possible 
to measure even small changes in heart function, blood flow and blood pressure and thus, better 
characterize the cardiovascular effects of various Pb(II) and mercury exposures. A group of control 
animals was run with each experiment to assure the quality of the study. For the data analysis, the 
selection of animals for the control group was based on normotensive blood pressure values. For 
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single metal exposures, 7-8 different doses per metal were applied allowing the derivation of safe 
thresholds of exposure. For combined metal exposures, the selected ratios were based on published 
reference and environmental exposure values, which renders them particularly relevant for human 
exposure scenarios. The exposure scenarios of first single metal exposure and then combined metal 
exposures allowed for a unique comparison of cardiovascular effects between one metal and a 
metal mixture. As a consequence, it was also possible to compare the mechanisms for 
cardiovascular toxicity of single and combined metal exposures.  
The few limitations of the presented research include the sub-chronic exposure duration versus 
chronic exposure in humans, the use of only male rats, tap water and the low number of animals per 
group. However, the listed strengths outnumber the study limitations and the applied high-sensitivity 
methods add confidence to the findings.  
6.3 Future research 
The presented research showed that exposure to Pb(II), Hg(II) and MeHg(I) and their mixtures can 
adversely affect the cardiovascular system and thus, impair public health. Future studies should 
investigate the influence of exposure duration on the cardiovascular system to better relate effects 
from short-term exposures in animals to long-term exposure in human adults. Epidemiological 
studies have shown gender differences in the development of hypertension (Sandberg and Ji, 2012), 
which were not addressed in this research. Therefore, it will be important to explore the impact of 
gender on blood pressure, heart function, blood flow and electrical activity of the heart to prevent 
cardiovascular deaths.  
Epidemiological studies play a crucial role in characterization of cardiovascular effects and to 
establish reference values for safe levels of exposure. However, previous studies should be re-
analyzed to consider mixture effects due to combined exposure to Pb(II) and mercury and mixture 
ratios be calculated. As blood pressure was not the most sensitive end-point for mixture effects, 
these studies should include a variety of cardiovascular end-points to better estimate the overall 
cardiovascular risk. Future human studies should include these factors in their experimental designs, 
which improve the understanding of the cardiovascular risk due to Pb(II) and mercury exposure.   
Future studies should also explore the underlying mechanisms for cardiovascular toxicity. The 
research results showed that no single mechanism is responsible for the adverse effects and that 
the mechanism might differ depending on single or combined exposures. It is also not understood 
how epigenetic mechanisms, in particular DNA methylation, affect the cardiovascular system. Future 
studies should investigate which genes relevant for cardiovascular health are affected by Pb(II) or 
 81 
mercury exposure. Once such changes are identified, it might be possible to identify biomarkers for 
increased cardiovascular risk.  
A well-populated database for cardiovascular effects from exposures to Pb(II), Hg(II) and MeHg(I) 
and their mixtures will allow regulatory toxicologists in establishing safe exposure thresholds and 
provide a useful tool for predicting cardiovascular risks from metals with similar properties, e.g. 
cadmium. Overall, a detailed knowledge of the cardiovascular system at physiological, cellular and 
molecular levels due to exposure to Pb(II) and mercury will improve the protection of public health.     
6.4 Conclusions 
Lead and mercury species are traditionally known as neurotoxicants and most of the research has 
been carried out on their effects on the nervous system. Over the last decades, a growing number of 
studies indicate an association between exposure to lead or mercury species and adverse 
cardiovascular effects. However, their adverse effects on the cardiovascular system are poorly 
characterized and mixture effects are almost completely unknown. The presented research could 
broaden the understanding of the range of cardiovascular effects elicited by these metals but also 
that there are clear differences between each metal. The finding that mixtures of Pb(II), Hg(II) and 
MeHg(I) deviate from additivity raises the question if the general population is protected or not. 
Mechanisms for cardiovascular toxicity due to exposure to Pb(II), Hg(II) and MeHg(I) are partly 
understood, little is known about their mechanistic interactions or the influence of epigenetics. The 
research results were able to answer some questions but also raised many new questions, which 
will hopefully be addressed by future research projects.   
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8 APPENDICES 
8.1 Appendix A: Supplemental data for study 1 (chapter 3) 
Supplemental table S8.1. Baseline echocardiographic and ultrasound values for rats obtained 1-day prior to starting 4-week oral 
exposures to lead, inorganic mercury or methylmercury. Values for each individual rat were used to correct subsequent measurements 
after 4-weeks exposure to indicate change caused by treatment. 
Experimental 
dose 
(µg/kg-bw/d) 
Heart free wall 
thickness systole (mm) 
at baseline 
Heart free wall thickness 
diastole (mm) 
at baseline 
Carotid artery 
diameter (mm) 
at baseline 
Carotid artery wall 
thickness 
at baseline 
Peak carotid 
velocity (mm/s) 
at baseline 
MeHg  
4 0.79 ± 0.1 0.70 ± 0.09 0.73 ± 0.07 0.49 ± 0.06 -740 ± 110 
7 0.76 ± 0.05 0.66 ± 0.04 0.90 ± 0.04 0.45 ± 0.04 -685 ± 116 
14 0.74 ± 0.11 0.71 ± 0.12 0.95 ± 0.12 0.46 ± 0.04 -591 ± 155 
29 0.76 ± 0.09 0.69 ± 0.08 0.81 ± 0.04 0.47 ± 0.03 -853 ± 153 
57 0.74 ± 0.08 0.71 ± 0.06 0.83 ± 0.18 0.46 ± 0.03 -772 ± 63 
357 0.71 ± 0.08 0.71 ± 0.07 0.91 ± 0.08 0.46 ± 0.02 -595 ± 189 
1607 0.73 ± 0.06 0.70 ± 0.08 0.88 ± 0.04 0.45 ± 0.02 -653 ± 146 
No significant differences among treatment groups were detected using 1-way ANOVA for any end-points at baseline. 
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Supplemental figure S8.1. End-diastolic volume (EDV), end-systolic volume (ESV) and ejection 
fraction determined using echocardiography in rats exposed to lead (left column), inorganic mercury 
(middle column) and methylmercury (right column) after 4 weeks of exposure via the drinking water: 
Results for EDV (A), ESV (B) and ejection fraction (C) are shown as mean ± SD. For every graph, 
the mean value (solid horizontal line) for the control group ± its SD (dotted lines) are shown. *p<0.05, 
**p<0.01 compared to control in Fisher’s LSD posteriori test after one-way ANOVA. n=5-6 
rats/group. 
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8.2 Appendix B: Supplemental data 
Peak systolic acceleration (PSA), peak velocity and velocity time interval (VTI) determined using 
echocardiography in rats exposed to lead (left column), inorganic mercury (middle column) and 
methylmercury (right column) at baseline and after four weeks of exposure via the drinking water: 
Results for PSA (A), peak velocity (B) and VTI (C) are shown as mean ± SD. For every graph, the 
mean value (solid horizontal line) for the control group ± its SD (dotted lines) are shown. *p<0.05, 
**p<0.01 compared to control in Fisher’s LSD posteriori test after one-way ANOVA. n=5-6 
rats/group. 
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An electrocardiogram (ECG) was recorded in rats exposed to lead (left column), inorganic mercury 
(middle column) and methylmercury (right column) after four weeks of exposure via the drinking 
water. Results for PR interval (A), QRS interval (B) and QT interval (C) are shown as mean ± SD. 
For every graph, the mean value (solid horizontal line) for the control group ± its SD (dotted lines) 
are shown. *p<0.05, **p<0.01 compared to control in Fisher’s LSD posteriori test after one-way 
ANOVA. n=5-6 rats/group. 
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End-systolic volume (ESV), end-diastolic volume (EDV) and stroke volume. Results are shows as 
the difference between week-4 and baseline. Row A: ESV, EDV and stroke volume for one-metal 
exposure of methylmercury (29 μg/kg-bw/day), Hg(II) (57 μg/kg-bw/day), Pb(II) (357 μg/kg-bw/day) 
and the reference value ratio [MeHg(I):Hg(II): Pb(II) = 29:87:203] and environmental exposure ratio 
[MeHg(I):Hg(II): Pb(II) = 29:58:493]; row B: ESV, EDV and stroke volume for one-metal exposure of 
methylmercury (357 μg/kg-bw/day), Hg(II) (357 μg/kg-bw/day), Pb(II) (1607 μg/kg-bw/day) and the 
reference value ratio [MeHg(I):Hg(II): Pb(II) = 290:870:2030] and the environmental exposure ratio 
[MeHg(I):Hg(II): Pb(II) = 290:580:4930]; unpaired Student’s t-test *p = 0.01–0.05, **p = 0.001–0.01, 
***p = 0.001–0.0001, ****p<0.0001. 
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Carotid diameter and free wall thickness of the carotid. Results are shows as the difference between 
week-4 and baseline. Row A: carotid diameter and free wall thickness for one-metal exposure of 
methylmercury (29 μg/kg-bw/day), Hg(II) (57 μg/kg-bw/day), Pb(II) (357 μg/kg-bw/day) and the 
reference value ratio [MeHg(I):Hg(II): Pb(II) = 29:87:203] and environmental exposure ratio 
[MeHg(I):Hg(II): Pb(II) = 29:58:493]; row B: carotid diameter and free wall thickness for one-metal 
exposure of methylmercury (357 μg/kg-bw/day), Hg(II) (357 μg/kg-bw/day), Pb(II) (1607 μg/kg-
bw/day) and the reference value ratio [MeHg(I):Hg(II): Pb(II) = 290:870:2030] and the environmental 
exposure ratio [MeHg(I):Hg(II): Pb(II) = 290:580:4930]; unpaired Student’s t-test *p = 0.01–0.05, **p 
= 0.001–0.01, ***p = 0.001–0.0001, ****p<0.0001. 
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Peak velocity, peak systolic acceleration (PSA) and velocity time interval (VTI). Results are shows 
as the difference between week-4 and baseline. Row A: peak velocity, PSA and VTI for one-metal 
exposure of methylmercury (29 μg/kg-bw/day), Hg(II) (57 μg/kg-bw/day), Pb(II) (357 μg/kg-bw/day) 
and the reference value ratio [MeHg(I):Hg(II): Pb(II) = 29:87:203] and environmental exposure ratio 
[MeHg(I):Hg(II): Pb(II) = 29:58:493]; row B: peak velocity, PSA and VTI for one-metal exposure of 
methylmercury (357 μg/kg-bw/day), Hg(II) (357 μg/kg-bw/day), Pb(II) (1607 μg/kg-bw/day) and the 
reference value ratio [MeHg(I):Hg(II): Pb(II) = 290:870:2030] and the environmental exposure ratio 
[MeHg(I):Hg(II): Pb(II) = 290:580:4930]; unpaired Student’s t-test *p = 0.01–0.05, **p = 0.001–0.01, 
***p = 0.001–0.0001, ****p<0.0001. 
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Heart free wall thickness in systole and diastole. Results are shows as the difference between week-
4 and baseline. Row A: heart free wall thickness in systole and diastole for one-metal exposure of 
methylmercury (29 μg/kg-bw/day), Hg(II) (57 μg/kg-bw/day), Pb(II) (357 μg/kg-bw/day) and the 
reference value ratio [MeHg(I):Hg(II): Pb(II) = 29:87:203] and environmental exposure ratio 
[MeHg(I):Hg(II): Pb(II) = 29:58:493]; row B: heart free wall thickness in systole and diastole for one-
metal exposure of methylmercury (357 μg/kg-bw/day), Hg(II) (357 μg/kg-bw/day), Pb(II) (1607 μg/kg-
bw/day) and the reference value ratio [MeHg(I):Hg(II): Pb(II) = 290:870:2030] and the environmental 
exposure ratio [MeHg(I):Hg(II): Pb(II) = 290:580:4930]; unpaired Student’s t-test *p = 0.01–0.05, **p 
= 0.001–0.01, ***p = 0.001–0.0001, ****p<0.0001. 
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